




(86) **Date de dépôt PCT/PCT Filing Date:** 2019/02/13
 (87) **Date publication PCT/PCT Publication Date:** 2019/08/22
 (45) **Date de délivrance/Issue Date:** 2023/06/27
 (85) **Entrée phase nationale/National Entry:** 2020/06/26
 (86) **N° demande PCT/PCT Application No.:** US 2019/017749
 (87) **N° publication PCT/PCT Publication No.:** 2019/160890
 (30) **Priorité/Priority:** 2018/02/13 (US62/629,753)

(51) **Cl.Int./Int.Cl.** C07J 43/00 (2006.01)
 (72) **Inventeurs/Inventors:**
 GRAY, NATHANAEL S., US;
 HATCHER, JOHN, US
 (73) **Propriétaire/Owner:**
 DANA-FARBER CANCER INSTITUTE, INC., US
 (74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) **Titre : AGENTS DE DEGRADATION DE KINASE DEPENDANTE DE LA CYCLINE ET PROCEDES D'UTILISATION**
 (54) **Title: CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE**



(57) **Abrégé/Abstract:**

The present application provides bifunctional compounds of Formula (Ia): (Ia), or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or more of cyclin-dependent kinase 8 (CDK8) and cyclin-dependent kinase 19 (CDK19). The present application also relates to methods for the targeted degradation of CDK8 and/or CDK19 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 and/or CDK19 which can be utilized in the treatment of disorders modulated by CDK8 and/or CDK19.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 August 2019 (22.08.2019)(10) International Publication Number
WO 2019/160890 A1(51) International Patent Classification:
C07J 43/00 (2006.01)(21) International Application Number:
PCT/US2019/017749(22) International Filing Date:
13 February 2019 (13.02.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/629,753 13 February 2018 (13.02.2018) US(71) Applicant: **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 450 Brookline Avenue, Boston, MA 02215 (US).(72) Inventors: **GRAY, Nathanael, S.**; 26 Greenview Avenue, Boston, MA 02130 (US). **HATCHER, John**; 4115 Willow Trail, Marlborough, MA 01752 (US).(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Avenue, Suite 700, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE





FIG. 1

(57) **Abstract:** The present application provides bifunctional compounds of Formula (Ia): (Ia), or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or more of cyclin-dependent kinase 8 (CDK8) and cyclin-dependent kinase 19 (CDK19). The present application also relates to methods for the targeted degradation of CDK8 and/or CDK19 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 and/or CDK19 which can be utilized in the treatment of disorders modulated by CDK8 and/or CDK19.



WO 2019/160890 A1

CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE

5

BACKGROUND

Cyclin-dependent kinase is a kinase family integrating multiple signaling pathways to control either cell cycle or gene transcription. CDK1, 2, 4 and 6 are the critical enzymes that drive cell cycle transition. CDK7, 9 and 12 are known enzymes that regulate transcription instead of directly promoting cell cycles. CDK8 forms part of a mediator complex that regulates the transcriptional activity of RNA polymerase II, and thereby regulates cellular proliferation and differentiation. CDK8 has also been shown to modulate the transcriptional output from distinct transcription factors involved in oncogenic control, including the Wnt/ β -catenin pathway, Notch, p53, and TGF- β . CDK8 has been found to be amplified and overexpressed in colon and gastric cancer by acting through the Wnt pathway and its key signaling molecule β -catenin. In addition, CDK8 gene expression correlates with increased mortality in breast and ovarian cancers, and is essential for cell proliferation in melanoma. Similar to CDK8, CDK19 is one of the components of this mediator co-activator complex.

Ubiquitin-Proteasome Pathway (UPP) is a critical pathway that regulates proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases. These ligases comprise over 500 different proteins and are categorized into multiple classes defined by the structural element of their E3 functional activity. For example, cereblon (CRBN) interacts with damaged DNA binding protein 1 and forms an E3 ubiquitin ligase complex with Cullin 4 in which the proteins recognized by CRBN are ubiquitinated and degraded by proteasomes. Various immunomodulatory drugs (IMiDs) bind to CRBN and modulate CRBN's role in the ubiquitination and degradation of protein factors involved in maintaining regular cellular function. Bifunctional compounds composed of a target protein-binding moiety and an


E3 ubiquitin ligase-binding moiety have been shown to induce proteasome-mediated degradation of selected proteins.

Deregulation of CDKs has been shown to have a significant impact on the cell state and is frequently identified as oncogenic. Numerous selective or pan-CDK small molecule inhibitors have been identified, however, most of the known inhibitors have failed in clinic trials due to the lack of high systemic drug concentration. Alternative strategies to inhibit cyclin-dependent kinases, such as CDK8 and/or CDK19, are needed. At present, compounds with alternative mechanisms of action targeting CDK8 and/or CDK19 are not available. The present application addresses the need.

10

SUMMARY

The present application relates to novel bifunctional compounds, which function to recruit CDK8 and/or CDK19 to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof. The bifunctional compound is of Formula X:



15 wherein:

the Targeting Ligand is capable of binding to CDK8 and/or CDK19;


the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and

the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (*e.g.*, cereblon).

20

The present application also relates to targeted degradation of CDK8 and/or CDK19 through the use of bifunctional compounds, including bifunctional compounds that link an E3 ubiquitin ligase-binding moiety to a ligand that binds to CDK8 and/or CDK19.

The present application also relates to a bifunctional compound of Formula Ia:




25

Targeting Ligand

or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein:

X, u, v, w, y, z, and Het₁ are each as defined herein;



and the Degron;

the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (*e.g.*,
5 cereblon); and

the Targeting Ligand is capable of binding to CDK8 and/or CDK19.

The present application also relates to a pharmaceutical composition comprising a
therapeutically effective amount of a bifunctional compound of the application, or an
enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, and a
10 pharmaceutically acceptable carrier.

Another aspect of the present application relates to a method of modulating (*e.g.*,
inhibiting or decreasing the amount of) a kinase (*e.g.*, a cyclin-dependent kinase, such as CDK8
and/or CDK19). The method comprises administering to a subject in need thereof an effective
amount of a bifunctional compound of the application, or an enantiomer, diastereomer,
15 stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the
application.

Another aspect of the present application relates to a method of treating or preventing a
disease (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role). The method comprises
administering to a subject in need thereof an effective amount of a bifunctional compound of the
20 application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt
thereof, or a pharmaceutical composition of the application. In one aspect, the disease is a kinase
(*e.g.*, CDK8 and/or CDK19) mediated disorder. In one aspect, the disease is a proliferative
disease (*e.g.*, a proliferative disease in which CDK8 and/or CDK19 plays a role).

Another aspect of the present application relates to a method of treating or preventing
25 cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or an
activated CDK19 or wherein the subject is identified as being in need of CDK8 and/or CDK19
inhibition for the treatment or prevention of cancer. The method comprises administering to the
subject an effective amount of a bifunctional compound of the application, or an enantiomer,

diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application.

Another aspect of the present application relates to a kit comprising a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof.

Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, CDK8 and/or CDK19).

Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for treating or preventing a disease (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role). In one aspect, the disease is a kinase (*e.g.*, CDK8 and/or CDK19) mediated disorder. In one aspect, the disease is a proliferative disease (*e.g.*, a proliferative disease in which CDK8 and/or CDK19 plays a role).

Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for treating or preventing cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or an activated CDK19 or wherein the subject is identified as being in need of CDK8 and/or CDK19 inhibition for the treatment or prevention of cancer.

Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, CDK8 and/or CDK19).

Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in treating or preventing a disease (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role). In one aspect, the disease is

a kinase (*e.g.*, CDK8 and/or CDK19) mediated disorder. In one aspect, the disease is a proliferative disease (*e.g.*, a proliferative disease in which CDK8 and/or CDK19 plays a role).

Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in treating or preventing
5 cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or an activated CDK19 or wherein the subject is identified as being in need of CDK8 and/or CDK19 inhibition for the treatment or prevention of cancer.

Another aspect of the present application relates to use of a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, in modulating (*e.g.*, inhibiting or
10 decreasing the amount of) a kinase (*e.g.*, CDK8 and/or CDK19).

Another aspect of the present application relates to use of a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, in treating or preventing a disease
15 (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role). In one aspect, the disease is a kinase (*e.g.*, CDK8 and/or CDK19) mediated disorder. In one aspect, the disease is a proliferative disease (*e.g.*, a proliferative disease in which CDK8 and/or CDK19 plays a role).

Another aspect of the present application relates to use of a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, in treating or preventing cancer in a
20 subject, wherein the cell of the cancer comprises an activated CDK8 and/or an activated CDK19 or wherein the subject is identified as being in need of CDK8 and/or CDK19 inhibition for the treatment or prevention of cancer.

25 The present application provides modulators (*e.g.*, degraders or inhibitors) of CDK8 and/or CDK19 that are therapeutic agents in the treatment or prevention of diseases such as cancer and metastasis.

The present application further provides compounds and compositions with an improved efficacy and/or safety profile relative to known CDK8 and/or CDK19 inhibitors. The present
30 application also provides agents with novel mechanisms of action toward CDK8 and/or CDK19 kinases in the treatment of various types of diseases including cancer and metastasis.

The compounds and methods of the present application address unmet needs in the treatment of diseases or disorders in which pathogenic or oncogenic endogenous proteins (*e.g.*, CDK8 and/or CDK19) play a role, such as cancer.

The details of the disclosure are set forth in the accompanying description below.

5 Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, illustrative methods and materials are now described. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms
10 also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

The contents of all references (including literature references, issued patents, published
15 patent applications, and co-pending patent applications) cited throughout this application are not admitted to be prior art to the application.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a western blot showing the levels of CDK8, pS727-STAT1, and actin in Jurkat
20 cells treated with 0.1 μ M or 1 μ M Compound I-1 for either 6 h or 24 h.

FIG. 2 is a western blot showing the levels of CDK8, pS727-STAT1, and actin in MC38 colorectal cancer cells treated with 50 nM, 100 nM, 500 nM, or 1 μ M Compound I-1 for either 6 h or 24 h.

FIG. 3 is a western blot showing the levels of CDK8 and actin in WT Molt4 cells or
25 *CRBN*^{-/-}Molt4 cells treated with 0.1 μ M or 1 μ M Compound I-1.

FIG. 4 is a western blot illustrating inhibition of phosphorylation of S727-STAT1, a known CDK8 substrate, to form pS727-STAT1. pS727-STAT1 and total STAT1 were from HepG2 cells independently treated for 18 h with interferon gamma (IFN γ) and 0.5 μ M, 1 μ M, or 5 μ M Compound 33, or with IFN γ and 0.1 μ M or 1 μ M dehydrocortistatin A ("DCA"). DCA

has an CDK8 IC₅₀ value of 17 nM. Compound 33 and DCA induced dose-dependent inhibition of S727 phosphorylation in HepG2 cells.

FIG. 5 is a western blot showing the levels of CDK8, pS727-STAT1, and actin in Jurkat cells independently treated with 0.1 μM or 1 μM Compound I-1 or Compound I-4 for either 6 h
5 or 24 h.

FIG. 6 is a western blot showing the levels of CDK8 and actin in WT Molt4 cells or *CRBN*^{-/-}Molt4 cells treated with increasing concentrations of Compound I-1. Lysates were analyzed after 24 h.

FIG. 7 is a western blot showing the levels of CDK8 and actin in Jurkat cells treated with
10 increasing concentrations of Compound I-2. Lysates were analyzed after 24 h.


FIG. 8 is a western blot showing the levels of CDK8 and actin in Jurkat cells treated with increasing concentrations of Compound I-5. Lysates were analyzed after 24 h.

DETAILED DESCRIPTION

15 Compounds of the Application

The present application relates to bifunctional compounds having utility as modulators of ubiquitination and proteosomal degradation of targeted proteins, especially compounds comprising a moiety capable of binding to a polypeptide or a protein that is degraded and/or otherwise inhibited by the bifunctional compounds of the present application. In particular, the present application is directed to compounds which contain a moiety, *e.g.*, a small molecule
20 moiety (*i.e.*, having a molecular weight of below 2,000, 1,000, 500, or 200 Daltons), such as a thalidomide-like moiety, which is capable of binding to an E3 ubiquitin ligase, such as cereblon, and a ligand that is capable of binding to a target protein, in such a way that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and/or inhibition) of that
25 protein.

In one embodiment, the present application provides a bifunctional compound of Formula X:




wherein:

30 the Targeting Ligand is capable of binding to CDK8 and/or CDK19;

the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (*e.g.*, cereblon).

In one embodiment, the present application provides a compound of Formula Ia:



or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein:

X, u, v, w, y, z, and Het₁ are each as defined herein;


10

the Linker is a group that covalently binds to X and the Degron; the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (*e.g.*, cereblon); and the Targeting Ligand is capable of binding to CDK8 and/or CDK19.

Targeting Ligand

15 Targeting Ligand (TL) (or target protein moiety or target protein ligand or ligand) is a small molecule which is capable of binding to a target protein of interest, such CDK8 and/or CDK19.

In one embodiment, a Targeting Ligand is a compound of Formula TL-I:




20 or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein:

X is -O-, -NR₅-, or -Het₂-;


R₅ is H or C₁-C₆ alkyl;

Het₂ is a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and oxygen;


5 u, v, and w together form (i), (ii), or (iii):



y and z together form (iv) or (v):



Het₁ is heteroaryl comprising one or two 5- or 6-membered rings and 1-4 heteroatoms
10 selected from nitrogen, sulfur, and oxygen, and optionally substituted with NH₂;

wherein the Targeting Ligand is bonded to a Linker via the .

For a compound of Formula TL-I, in various embodiments where applicable, X, u, v, w, y, z, R₅, Het₁, and Het₂ are each as described below.

In one embodiment, X is -O-. In one embodiment, X is (R)-O-. In one embodiment, X
15 is (S)-O-.

In one embodiment, X is -NR₅-. In one embodiment, X is (R)-NR₅-. In one embodiment, X is (S)-NR₅-.

In one embodiment, X is -O-, (S)-O-, (R)-O-, -NR₅-, (S)-NR₅-, or (R)-NR₅-.

R or S configuration may be determined by methods readily known in art, such as by
20 assigning priority groups about a stereogenic carbon.

In one embodiment, R₅ is H.

In one embodiment, R₅ is C₁-C₆ straight-chain or C₃-C₆ branched alkyl (e.g., methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *s*-butyl, *t*-butyl, pentyl, or hexyl).

In one embodiment, R₅ is C₁-C₄ straight-chain or C₃-C₄ branched alkyl (e.g., methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *s*-butyl, or *t*-butyl).
25


In one embodiment, R₅ is C₁-C₆ alkyl optionally substituted with OH, O-(C₁-C₆ alkyl), NH₂, NH(C₁-C₆ alkyl), or N(C₁-C₆ alkyl)₂.

In one embodiment R_5 is methyl.


In one embodiment, X is $-\text{Het}_2-$. In one embodiment, X is (*R*)- Het_2- . In one embodiment, X is (*S*)- Het_2- .

In one embodiment, Het_2 is a 3- to 7-membered heterocyclic ring. In one embodiment, the heterocyclic ring is selected from aziridine, azetidine, pyrrolidine, dihydropyrrole, piperidine, piperazine, dihydropyridine, tetrahydropyridine, azepane, oxaziridine, oxazetidine, isoxazoline, isoxazolidine, oxazoline, oxazolidine, thiazoline, thiazolidine, isothiazoline, isothiazolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, morpholine, oxazinane, thiomorpholine, thiazinane, or the like. In one embodiment, the heterocyclic ring is morpholine. In one embodiment, Het_2 is a 5-, 8-, or 9-membered heteroaryl ring (e.g., pyrrole, pyrazole, imidazole, triazole, tetrazole, indole, benzimidazole, indazole, azaindole and the like). In one embodiment, the heteroaryl ring is selected from pyrrole, imidazole, 1,2,3-triazole, 1,2,4-triazole, and tetrazole. In one embodiment, the heteroaryl ring is triazole. In one embodiment, the heteroaryl ring is 1,2,3-triazole;


15 In one embodiment, u, v, and w together form




In one embodiment, u, v, and w together form




In one embodiment, u, v, and w together form



In one embodiment, y and z together form



In one embodiment, y and z together form




20 In one embodiment, Het_1 is heteroaryl selected from isoquinolinyl, quinolinyl, indazolyl, cinnolinyl, phthalazinyl, pyridinyl, pyridazinyl, indolyl, acridinyl, pyrazinyl, benzoquinolinyl, pyrazolyl, pyrrolyl, pyrimidinyl, purinyl, pyrrolopyrimidinyl, quinoxalinyl, and quinazolinyl. In


one embodiment, Het₁ is selected from 6-isoquinolinyl, 7-isoquinolinyl, 6-quinazoliny, 6-phthalazinyl, 6-indazolyl, 6-indazolyl-3-amine, and 5-indazolyl. In one embodiment, Het₁ is 7-isoquinolinyl.

In one embodiment, Het₁ is in the *R* configuration. In one embodiment, Het₁ is in the *S* configuration.


In one embodiment, a Targeting Ligand is not a compound of the following formula



Any of the groups described herein for any of X, u, v, w, y, z, R₅, Het₁, and Het₂ can be combined with any of the groups described herein for one or more of the remainder of X, u, v, w, y, z, R₅, Het₁, and Het₂.




(1) In one embodiment, u, v, and w together form (i), and y and z together




form (iv).




(2) In one embodiment, u, v, and w together form (ii), and y and z together




form (iv).




(3) In one embodiment, u, v, and w together form (iii), and y and z together




form (iv).




(4) In one embodiment, u, v, and w together form (i), and y and z together




form (v).




(5) In one embodiment, u, v, and w together form (ii), and y and z together



form (v).



5 (6) In one embodiment, u, v, and w together form (iii), and y and z together



form (v).

(7) In one embodiment, u, v, w, y, and z are each as defined and combined in any one of (1)-(6), and X is $-\text{O}-$. In a further embodiment, X is $(S)-\text{O}-$. In a further embodiment, X is $(R)-\text{O}-$.

10 (8) In one embodiment, u, v, w, y, and z are each as defined and combined in any one of (1)-(6), and X is $-\text{NR}_5-$. In a further embodiment, X is $(R)-\text{NR}_5-$. In a further embodiment, X is $(S)-\text{NR}_5-$.

(9) In one embodiment, u, v, w, y, and z are each as defined and combined in any one of (1)-(6), and X is $-\text{Het}_2-$. In a further embodiment, X is $(R)-\text{Het}_2-$. In a further embodiment, X is $(S)-\text{Het}_2-$.

15 (10) In one embodiment, u, v, w, y, z, and X are each as defined and combined, where applicable, in any one of (1)-(6) and (8), and R_5 is $\text{C}_1\text{-C}_6$ alkyl as described herein. In a further embodiment, R_5 is methyl.


(11) In one embodiment, u, v, w, y, z, and X are each as defined and combined, where applicable, in any one of (1)-(6) and (8), and R₅ is H.

(12) In one embodiment, u, v, w, y, z, X, and R₅ are each as defined and combined, where applicable, in any one of (1)-(11), and Het₁, where applicable, is in the (S) configuration.

5 (13) In one embodiment, u, v, w, y, z, X, and R₅ are each as defined and combined, where applicable, in any one of (1)-(11), and Het₁ is heteroaryl comprising two 5- or 6-membered rings and 1-4 heteroatoms selected from nitrogen, sulfur, and oxygen. In a further embodiment, Het₁ is heteroaryl comprising two 5- or 6-membered rings and 1-4 nitrogen atoms. In a further embodiment, Het₁, where applicable, is in the (S) configuration. In one embodiment, Het₁ is
10 selected from the heteroaryl groups described herein.

(14) In one embodiment, u, v, w, y, z, X, and Het₁ are each as defined and combined, where applicable, in any one of (1)-(6), (9), (12), and (13), Het₂ is a 3- to 7-membered heterocyclic or 5-, 8-, or 9-membered heteroaryl ring. In one embodiment, Het₂ is a 3- to 7-membered heterocyclic ring. In one embodiment, Het₂ is a 5-, 8-, or 9-membered heteroaryl
15 ring. In one embodiment, Het₂ is selected from the heterocyclic groups described herein. In one embodiment, Het₂ is selected from the heteroaryl groups described herein.

In one embodiment, a compound of Formula TL-I is of Formula (i'), (ii'), (iii'), (iv(a)), (iv(b)), (iv(c)), (v(a)), (v(b)), or (v(c)):



For a compound of Formula (i'), (ii'), (iii'), (iv(a)), (iv(b)), (iv(c)), (v(a)), (v(b)), or (v(c)), where applicable:

In one embodiment, X is $\text{--NR}_5\text{--}$. For example, X is $\text{--N(CH}_3\text{)--}$ or --NH-- .

5 In one embodiment, X is --O-- .


In one embodiment, X is $\text{--Het}_2\text{--}$ and Het₂ is a morpholinyl ring.

In one embodiment, X is $\text{--Het}_2\text{--}$ and Het₂ is piperazinyl ring.


In one embodiment, X is $\text{--Het}_2\text{--}$ and Het₂ is triazolyl ring.

10 In one embodiment, the carbon to which X is attached is designated with *R* stereochemistry (*i.e.*, X is (*R*) $\text{--NR}_5\text{--}$, (*R*) --O-- , or (*R*) $\text{--Het}_2\text{--}$).

In one embodiment, the carbon to which X is attached is designated with *S* stereochemistry (*i.e.*, X is (*S*) $\text{--NR}_5\text{--}$, (*S*) --O-- , or (*S*) $\text{--Het}_2\text{--}$).




In one embodiment, y and z together form



In one embodiment, y and z together form

In one embodiment, a compound of Formula TL-I is of Formula (iv(a)'), (v(a)'), (iv(a)'''), (v(a)'''), (iv(b)'), (v(b)'), (iv(b)'''), (v(b)'''), (iv(c)'), (v(c)'), (iv(c)'''), or (v(c)'''):



5 wherein:

X is $-O-$, $-NR_5-$, or $-Het_2-$;

R_5 is H or C_1-C_6 alkyl; and

Het₂ is a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and oxygen.

10

In one embodiment, X is $-O-$.

In one embodiment, X is $-NR_5-$.

In one embodiment, X is $-NR_5-$ and R_5 is methyl.

In one embodiment, X is $-NR_5-$ and R_5 is H.

15

In one embodiment, X is $-Het_2-$.

In one embodiment, X is --Het₂-- and Het₂ is a morpholinyl ring.


In one embodiment, X is --Het₂-- and Het₂ is piperazinyl ring.

In one embodiment, X is --Het₂-- and Het₂ is triazolyl ring.

In one embodiment, a compound of Formula TL-I is of Formula (iv(a)'), (v(a)'), (iv(a)'), (v(a)'), (iv(b)'), (v(b)'), (iv(b)'), (v(b)'), (iv(c)'), or (v(c)'), as described above.

In one embodiment, a compound of Formula TL-I is of Formula (iv(c')) or (v(c')), as described above.

In one embodiment, a compound of Formula TL-I is of one of the following formulae:



10 wherein:

X is --O--, --NR₅--, or --Het₂--;

R₅ is H or C₁-C₆ alkyl;

Het₂ is a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and

15 oxygen;

a, b, c, and d are each independently CR₆ or N; and

each R₆ is independently H or NH₂.

In one embodiment, X is --O--.

In one embodiment, X is --NR₅--.

In one embodiment, X is $-\text{NR}_5-$ and R_5 is methyl.

In one embodiment, X is $-\text{NR}_5-$ and R_5 is H.

In one embodiment, b and d are each independently CR_6 ; a and c are each N; and one R_6 is H, and one R_6 is NH_2 .

5 In one embodiment, a, b, and d are each independently CR_6 ; c is N; and each R_6 is H.


In one embodiment, X is $-\text{Het}_2-$.

In one embodiment, X is $-\text{Het}_2-$ and Het_2 is a morpholinyl ring.

In one embodiment, X is $-\text{Het}_2-$ and Het_2 is piperazinyl ring.

10 In one embodiment, X is $-\text{Het}_2-$ and Het_2 is triazolyl ring.

In one embodiment, a compound of Formula TL-1 is of one of the following formulae:



wherein:

X is $-\text{O}-$, $-\text{NR}_5-$, or $-\text{Het}_2-$;

15 R_5 is H or C_1 - C_6 alkyl; and

Het_2 is a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and oxygen.

In one embodiment, X is $-\text{O}-$.

In one embodiment, X is $-\text{NR}_5-$.

In one embodiment, X is $-\text{NR}_5-$ and R_5 is methyl.

In one embodiment, X is $-\text{NR}_5-$ and R_5 is H.


In one embodiment, X is $-\text{Het}_2-$.

5 In one embodiment, X is $-\text{Het}_2-$ and Het_2 is a morpholinyl ring.

In one embodiment, X is $-\text{Het}_2-$ and Het_2 is piperazinyl ring.

In one embodiment, X is $-\text{Het}_2-$ and Het_2 is triazolyl ring.

In one embodiment, a compound of Formula TL-I is of one of the following formulae:



10 wherein:

X is $-\text{O}-$, $-\text{NR}_5-$, or $-\text{Het}_2-$;

R_5 is H or C_1 - C_6 alkyl;

Het_2 is a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring
optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and
15 oxygen;

R_7 is H or C_1 - C_6 alkyl;

e and f are each independently CR_8 or N; and

each R_8 is independently be H or NH_2 .

In one embodiment, X is $-\text{O}-$.

In one embodiment, X is $-\text{NR}_5-$.

In one embodiment, X is $-\text{NR}_5-$ and R_5 is methyl.

In one embodiment, X is $-\text{NR}_5-$ and R_5 is H.

In one embodiment, e is N; f is CR_8 ; and R_8 is H.

5 In one embodiment, e is N; f is CR_8 ; and R_8 is NH_2 .

In one embodiment, e is CR_8 ; f is N; R_8 is NH_2 ; and R_7 may be H.

In one embodiment, e is CR_8 ; f is N; R_8 is H; and R_7 may be H.

In one embodiment, X is $-\text{Het}_2-$.





In one embodiment, X is $-\text{Het}_2-$ and Het_2 is a morpholinyl ring.


10 In one embodiment, X is $-\text{Het}_2-$ and Het_2 is piperazinyl ring.


In one embodiment, X is $-\text{Het}_2-$ and Het_2 is triazolyl ring.









In several embodiments, a compound of Formula TL-I may be represented by one of compounds in the right column in Table 1, where the left column shows the structure of the compounds from which a compound of Formula TL-I may be prepared.









15 **Table 1**









Cmpd No.	Structure	Moiety No.	Structure
1		A	
2		B	

















10		K	
11		L	
12		M	
13		N	

14		O	
22r		P*	
23		Q ^o	
24		R*	

25		S*	
32		T*	
33		U*	
34		V	

38		W ^D	
39		X ^D	
45		Y	
46		Z	


47		AA	
48		BB	

^φ Target-Linker-Degrons I-1, I-2, and I-3 prepared from compound 46.


* Target-Linker-Degrons may be prepared from mono-methylated derivative.

^p Target-Linker-Degron may be prepared by, for example, via General Scheme 2.


5 In several embodiments, a compound of Formula TL-I may be represented by one of:




In several embodiments, a compound of Formula TL-I may be represented by one of:




In several embodiments, a compound of Formula TL-I may be represented by one of:




In several embodiments, a compound of Formula TL-I may be represented by one of:




In several embodiments, a compound of Formula TL-I may be represented by one of:







In several embodiments, a compound of Formula TL-I may be represented by one of:




In some embodiments, a compound of Formula TL-I may be represented by one of:




In some embodiments, a compound of Formula TL-I may be represented by one of:




In some embodiments, a compound of Formula TL-I may be represented by one of:




In some embodiments, a compound of Formula TL-I may be represented by one of:




In some embodiments, a compound of Formula TL-I may be represented by one of:



In some embodiments, a compound of Formula TL-I may be represented by one of:




In some embodiments, a compound of Formula TL-I may be represented by one of:



Degron

5 The Degron serves to link a targeted protein, through a Linker and a Targeting Ligand, to a ubiquitin ligase for proteosomal degradation. In one embodiment, the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase. In one embodiment, the Degron is capable of binding to cereblon.

In one embodiment, the Degron is of Formula D1:



10

or an enantiomer, diastereomer, or stereoisomer thereof, wherein:

Y is a bond, (CH₂)₁₋₆, (CH₂)₀₋₆-O, (CH₂)₀₋₆-C(O)NR₁₁, (CH₂)₀₋₆-NR₁₁C(O), (CH₂)₀₋₆-NH,
or (CH₂)₀₋₆-NR₁₂;

Z₁ is C(O) or C(R₁₃)₂;

Z₂ is C(O) or C(R₁₃)₂;

5 R₁₁ is H or C₁-C₆ alkyl;

R₁₂ is C₁-C₆ alkyl or C(O)-C₁-C₆ alkyl;

each R₁₃ is independently H or C₁-C₃ alkyl;

each R₁₄ is independently C₁-C₃ alkyl;

R₁₅ is H, deuterium, C₁-C₃ alkyl, F, or Cl;

10 each R₁₆ is independently halogen, OH, C₁-C₆ alkyl, or C₁-C₆ alkoxy;

q is 0, 1, or 2; and

s is 0, 1, 2, or 3,

wherein the Degron is covalently bonded to a Linker via $\frac{\xi}{\xi}$.

In one embodiment, Z₁ is C(O).

15 In one embodiment, Z₁ is C(R₁₃)₂; and each R₁₃ is H. In one embodiment, Z₁ is C(R₁₃)₂; and one of R₁₃ is H, and the other is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In one embodiment, Z₁ is C(R₁₃)₂; and each R₁₃ is independently selected from methyl, ethyl, and propyl.

In one embodiment, Z₂ is C(O).

20 In one embodiment, Z₂ is C(R₁₃)₂; and each R₁₃ is H. In one embodiment, Z₂ is C(R₁₃)₂; and one of R₁₃ is H, and the other is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In one embodiment, Z₂ is C(R₁₃)₂; and each R₁₃ is independently selected from methyl, ethyl, and propyl.

In one embodiment, Z₁ and Z₂ are each C(O).

25 In one embodiment, Z₁ is C(O); and Z₂ is C(R₁₃)₂ and each R₁₃ is H. In one embodiment, Z₂ is C(R₁₃)₂; and one of R₁₃ is H, and the other is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In one embodiment, Z₂ is C(R₁₃)₂; and each R₁₃ is independently selected from methyl, ethyl, and propyl.

In one embodiment, Y is a bond.

30 In one embodiment, Y is a bond, O, or NH.

In one embodiment, Y is (CH₂)₁, (CH₂)₂, (CH₂)₃, (CH₂)₄, (CH₂)₅, or (CH₂)₆. In one embodiment, Y is (CH₂)₁, (CH₂)₂, or (CH₂)₃. In one embodiment, Y is (CH₂)₁ or (CH₂)₂.

In one embodiment, Y is O, CH₂-O, (CH₂)₂-O, (CH₂)₃-O, (CH₂)₄-O, (CH₂)₅-O, or (CH₂)₆-O. In one embodiment, Y is O, CH₂-O, (CH₂)₂-O, or (CH₂)₃-O. In one embodiment, Y is O or
5 CH₂-O. In one embodiment, Y is O.

In one embodiment, Y is C(O)NR₁₁, CH₂-C(O)NR₁₁, (CH₂)₂-C(O)NR₁₁, (CH₂)₃-C(O)NR₁₁, (CH₂)₄-C(O)NR₁₁, (CH₂)₅-C(O)NR₁₁, or (CH₂)₆-C(O)NR₁₁. In one embodiment, Y is C(O)NR₁₁, CH₂-C(O)NR₁₁, (CH₂)₂-C(O)NR₁₁, or (CH₂)₃-C(O)NR₁₁. In one embodiment, Y is C(O)NR₁₁ or CH₂-C(O)NR₁₁. In one embodiment, Y is C(O)NR₁₁.

10 In one embodiment, Y is NR₁₁C(O), CH₂-NR₁₁C(O), (CH₂)₂-NR₁₁C(O), (CH₂)₃-NR₁₁C(O), (CH₂)₄-NR₁₁C(O), (CH₂)₅-NR₁₁C(O), or (CH₂)₆-NR₁₁C(O). In one embodiment, Y is NR₁₁C(O), CH₂-NR₁₁C(O), (CH₂)₂-NR₁₁C(O), or (CH₂)₃-NR₁₁C(O). In one embodiment, Y is NR₁₁C(O) or CH₂-NR₁₁C(O). In one embodiment, Y is NR₁₁C(O).

In one embodiment, R₁₁ is H. In one embodiment, R₁₁ is selected from methyl, ethyl,
15 propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl. In one embodiment, R₁₁ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In one embodiment, Y is NH, CH₂-NH, (CH₂)₂-NH, (CH₂)₃-NH, (CH₂)₄-NH, (CH₂)₅-NH, or (CH₂)₆-NH. In one embodiment, Y is NH, CH₂-NH, (CH₂)₂-NH, or (CH₂)₃-NH. In one embodiment, Y is NH or CH₂-NH. In one embodiment, Y is NH.

20 In one embodiment, Y is NR₁₂, CH₂-NR₁₂, (CH₂)₂-NR₁₂, (CH₂)₃-NR₁₂, (CH₂)₄-NR₁₂, (CH₂)₅-NR₁₂, or (CH₂)₆-NR₁₂. In one embodiment, Y is NR₁₂, CH₂-NR₁₂, (CH₂)₂-NR₁₂, or (CH₂)₃-NR₁₂. In one embodiment, Y is NR₁₂ or CH₂-NR₁₂. In one embodiment, Y is NR₁₂.

In one embodiment, R₁₂ is selected from methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl. In one embodiment, R₁₂ is C₁-C₃ alkyl selected from methyl, ethyl,
25 and propyl.

In one embodiment, R₁₂ is selected from C(O)-methyl, C(O)-ethyl, C(O)-propyl, C(O)-butyl, C(O)-i-butyl, C(O)-t-butyl, C(O)-pentyl, C(O)-i-pentyl, and C(O)-hexyl. In one embodiment, R₁₂ is C(O)-C₁-C₃ alkyl selected from C(O)-methyl, C(O)-ethyl, and C(O)-propyl.

In one embodiment, R₁₃ is H.

30 In one embodiment, R₁₃ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In one embodiment, R₁₃ is methyl.

In one embodiment, q is 0.

In one embodiment, q is 1.

In one embodiment, q is 2.

5 In one embodiment, each R₁₄ is independently C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In one embodiment, s is 0.

In one embodiment, s is 1.

In one embodiment, s is 2.

In one embodiment, s is 3.

10 In one embodiment, each R₁₆ is independently selected from halogen (*e.g.*, F, Cl, Br, and I), OH, C₁-C₆ alkyl (*e.g.*, methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl), and C₁-C₆ alkoxy (*e.g.*, methoxy, ethoxy, propoxy, butoxy, i-butoxy, t-butoxy, and pentoxy). In a further embodiment, each R₁₆ is independently selected from F, Cl, OH, methyl, ethyl, propyl, butyl, i-butyl, t-butyl, methoxy, and ethoxy.

15 In one embodiment, R₁₅ is H, deuterium, or C₁-C₃ alkyl. In another embodiment, R₁₅ is H or C₁-C₃ alkyl. In a further embodiment, R₁₅ is in the (*S*) or (*R*) configuration. In a further embodiment, R₁₅ is in the (*S*) configuration. In one embodiment, the compound comprises a racemic mixture of (*S*)-R₁₅ and (*R*)-R₁₅.

In one embodiment, R₁₅ is H.

20 In one embodiment, R₁₅ is deuterium.

In one embodiment, R₁₅ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl. In one embodiment, R₁₅ is methyl.

25 In one embodiment, R₁₅ is F or Cl. In a further embodiment, R₁₅ is in the (*S*) or (*R*) configuration. In a further embodiment, R₁₅ is in the (*R*) configuration. In one embodiment, the compound comprises a racemic mixture of (*S*)-R₁₅ and (*R*)-R₁₅. In one embodiment, R₁₅ is F.


Any of the groups described herein for any of Y, Z₁, Z₂, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, q and s can be combined with any of the groups described herein for one or more of the remainder of Y, Z₁, Z₂, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, R₁₆, q and s, and may further be combined with any of the groups described herein for the Linker.





















30 For a Degron of Formula D1:


(1) In one embodiment, Z₁ is C(O) and Y is a bond.

- (2) In one embodiment, Z_1 is C(O) and Y is NH.
- (3) In one embodiment, Z_1 is C(O) and Y is $(CH_2)_{0-6}-O$. In a further embodiment, Y is O.
- (4) In one embodiment, Z_1 is C(O); Y is a bond; and q and s are each 0.
- (5) In one embodiment, Z_1 is C(O); Y is NH; and q and s are each 0.
- 5 (6) In one embodiment, Z_1 is C(O); Y is $(CH_2)_{0-6}-O$; and q and s are each 0. In a further embodiment, Y is O.
- (7) In one embodiment, Z_1 is C(O); Y is a bond; and R_{13} is H.
- (8) In one embodiment, Z_1 is C(O); Y is a bond; and R_{15} is H.
- (9) In one embodiment, Z_1 is C(O); Y is NH; and R_{13} is H.
- 10 (10) In one embodiment, Z_1 is C(O); Y is NH; and R_{15} is H.
- (11) In one embodiment, Z_1 is C(O); Y is a bond; R_{13} is H; and R_{15} is H.
- (12) In one embodiment, Z_1 is C(O); Y is NH; R_{13} is H; and R_{15} is H.
- (13) In one embodiment, Z_1 is C(O); Y is $(CH_2)_{0-6}-O$; and R_{13} is H. In a further embodiment, Y is O.
- 15 (14) In one embodiment, Z_1 is C(O); Y is $(CH_2)_{0-6}-O$; and R_{15} is H. In a further embodiment, Y is O.
- (15) In one embodiment, Z_1 is C(O); Y is $(CH_2)_{0-6}-O$; R_{13} is H; and R_{15} is H. In a further embodiment, Y is O.
- (16) In one embodiment, q and s are each 0; and Y, Z_1 , R_{13} , R_{15} , and R_{16} are each as
- 20 defined in any of (1) – (3) and (7) – (15).
- (17) In one embodiment, Z_1 is C(O) and Z_2 is C(O).
- (18) In one embodiment, Z_1 is C(O); Z_2 is C(O); and R_{15} is H.
- (19) In one embodiment, Z_1 is C(O) and Z_2 is $C(R_{13})_2$.
- (20) In one embodiment, Z_1 is C(O); Z_2 is $C(R_{13})_2$; and R_{13} is H.
- 25 (21) In one embodiment, Z_1 is C(O); Z_2 is $C(R_{13})_2$; R_{13} is H; and R_{15} is H.

In one embodiment, the Degron is of one of the following formulae:



	(D1b),		(D1b'),
	(D1c),		(D1c'),
	(D1d),		(D1d'),
	(D1e),		(D1e'),
	(D1f),		(D1f'),
	(D1g),		(D1g'),
	(D1h),		(D1h'),
	(D1i),		(D1i'),
	(D1j),		(D1j'),
	(D1k),		(D1k'),



or an enantiomer, diastereomer, or stereoisomer thereof, wherein Y, R₁₃, R₁₄, R₁₆, q, and s are each as defined above in Formula D1, and can be selected from any moieties or combinations thereof described above.

5 In one embodiment, the Degron is one of the preceding formulae D1a-D11' and R₁₃ is H.

In one embodiment, the Degron is one of the preceding formulae D1a-D11' and R₁₃ is C₁-C₃ alkyl. In one embodiment, R₁₃ is CH₃.

In one embodiment, Y is a bond, O, or NH. In one embodiment, Y is a bond. In one embodiment, Y is O. In one embodiment, Y is NH.

10 Linker

The Linker is a bond or a carbon chain that serves to link a Targeting Ligand with a Degron. In one embodiment, the carbon chain optionally comprises one, two, three, or more heteroatoms selected from N, O, and S. In one embodiment, the carbon chain comprises only saturated chain carbon atoms. In one embodiment, the carbon chain optionally comprises two or
 15 more unsaturated chain carbon atoms (*e.g.*, C=C or C≡C). In one embodiment, one or more chain carbon atoms in the carbon chain are optionally substituted with one or more substituents (*e.g.*, oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₃ alkoxy, OH, halogen, NH₂, NH(C₁-C₃ alkyl), N(C₁-C₃ alkyl)₂, CN, C₃-C₈ cycloalkyl, heterocyclyl, phenyl, and heteroaryl).


20 In one embodiment, the Linker comprises at least 5 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises less than 25 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises less than 20 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises 5, 6,
 25 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises 5, 7, 9, 11, 13, 15, 17, or 19 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises 5, 7, 9, or 11 chain atoms (*e.g.*, C, O, N, and S). In one embodiment, the Linker comprises 11, 13, 15, 17, or 19 chain atoms (*e.g.*, C, O,

N, and S). In one embodiment, the Linker comprises 11, 13, 15, 17, 19, 21, or 23 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 6, 8, 10, 12, 14, 16, 18, or 20 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 6, 8, 10, or 12 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 12, 14, 16, 18, or 20 chain atoms (e.g., C, O, N, and S).

In one embodiment, the Linker comprises from 11 to 19 chain atoms (e.g., C, O, N, and S).

In one embodiment, the Linker is a carbon chain optionally substituted with non-bulky substituents (e.g., oxo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₃ alkoxy, OH, halogen, NH₂, NH(C₁-C₃ alkyl), N(C₁-C₃ alkyl)₂, and CN). In one embodiment, the non-bulky substitution is located on the chain carbon atom proximal to the Degron (i.e., the carbon atom is separated from the carbon atom to which the Degron is bonded by at least 3, 4, or 5 chain atoms in the Linker). In one embodiment, the non-bulky substitution is located on the chain carbon atom proximal to the Targeting Ligand (i.e., the carbon atom is separated from the carbon atom to which the Degron is bonded by at least 3, 4, or 5 chain atoms in the Linker).

In one embodiment, the Linker is of Formula L0:



or an enantiomer, diastereomer, or stereoisomer thereof, wherein

- 20 p1 is an integer selected from 0 to 12;
 p2 is an integer selected from 0 to 12;
 p3 is an integer selected from 0 to 6;
 each W is independently absent, CH₂, O, S, NH, or NR₁₉;
 Z₃ is absent, C(O), (CH₂)_jC(O)NH, CH₂, O, NH, or NR₁₉;
 25 each R₁₉ is independently C₁-C₃ alkyl;
 j is 1, 2, or 3; and
 Q is absent, CH₂, C(O), or NHC(O)CH₂,

wherein the Linker is covalently bonded to a Degron via the $\overset{\text{Z}}{\underset{\text{Q}}{\text{---}}}$ next to Q, and covalently bonded to a Targeting Ligand via the $\overset{\text{Z}}{\underset{\text{Z}_3}{\text{---}}}$ next to Z₃.

In one embodiment, the total number of chain atoms in the Linker is less than 30. In a further embodiment, the total number of chain atoms in the Linker is less than 20.

5 For a Linker of Formula L0:

In one embodiment, p1 is an integer selected from 0 to 10.

In one embodiment, p1 is an integer selected from 1 to 10.

In one embodiment, p1 is selected from 1, 2, 3, 4, 5, and 6.

In one embodiment, p1 is 0, 1, 3, or 5.

10 In one embodiment, p1 is 0, 1, 2, or 3.

In one embodiment, p1 is 0.

In one embodiment, p1 is 1.

In one embodiment, p1 is 3.

In one embodiment, p1 is 5.

15 In one embodiment, p2 is an integer selected from 0 to 10.

In one embodiment, p2 is selected from 0, 1, 2, 3, 4, 5, and 6.

In one embodiment, p2 is 0, 1, 2, or 3.

In one embodiment, p2 is 0.

In one embodiment, p2 is 1.

20 In one embodiment, p3 is an integer selected from 1 to 5.

In one embodiment, p3 is 2, 3, 4, or 5.

In one embodiment, p3 is 0, 1, 2, or 3.

In one embodiment, p3 is 0.

In one embodiment, p3 is 1.

25 In one embodiment, p3 is 2.

In one embodiment, p3 is 3.

In one embodiment, p3 is 6.

In one embodiment, at least one W is CH₂.

In one embodiment, at least one W is O.

30 In one embodiment, at least one W is S.

In one embodiment, at least one W is NH.

In one embodiment, at least one W is NR₁₉; and each R₁₉ is independently C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In one embodiment, each W is O.

5 In one embodiment, j is 1, 2, or 3.

In one embodiment, j is 1.

In one embodiment, j is 2.

In one embodiment, j is 3.

In one embodiment, j is 2 or 3.

10 In one embodiment, j is 1 or 2.

In one embodiment, Q is absent.

In one embodiment, Q is NHC(O)CH₂.

In one embodiment, Q is C(O).

In one embodiment, Q is CH₂.

15 In one embodiment, Z₃ is absent.

In one embodiment, Z₃ is CH₂.

In one embodiment, Z₃ is O.

In one embodiment, Z₃ is C(O).

In one embodiment, Z₃ is (CH₂)_jC(O)NH.

20 In one embodiment, Z₃ is NR₁₉; and R₁₉ is C₁-C₃ alkyl selected from methyl, ethyl, and propyl.

In one embodiment, p₁ is 1, 2, 3, or 4. In one embodiment, p₁ is 1. In one embodiment, p₁ is 2. In one embodiment, p₁ is 3. In one embodiment, p₁ is 4.

In one embodiment, p₁ is 1 and Z₃ is absent.

25 In one embodiment, p₁ is 1, Z₃ is absent, and W is CH₂.

In one embodiment, p₁ is 1, Z₃ is absent, and p₃ is 1.

In one embodiment, p₁ is 1, Z₃ is absent, and p₃ is 2.

In one embodiment, p₁ is 1, Z₃ is absent, and p₂ is 0.

In one embodiment, p₁ is 1, Z₃ is absent, p₃ is 2, and p₂ is 0.

30 In one embodiment, p₁ is 1, Z₃ is absent, p₃ is 2, p₂ is 0, and each W is O.

In one embodiment, p₁ is 1, Z₃ is absent, p₃ is 2, p₂ is 0, each W is O, and Q is absent.

In one embodiment, p1 is 3 and Z₃ is absent.

In one embodiment, p1 is 3, Z₃ is absent, and p3 is 2.

In one embodiment, p1 is 3, Z₃ is absent, and p2 is 0.

In one embodiment, p1 is 3, Z₃ is absent, p3 is 2, and p2 is 0.

5 In one embodiment, p1 is 3, Z₃ is absent, p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 3, Z₃ is absent, p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p1 is 5 and Z₃ is absent.

In one embodiment, p1 is 5, Z₃ is absent, and p3 is 2.

In one embodiment, p1 is 5, Z₃ is absent, and p2 is 0.

10 In one embodiment, p1 is 5, Z₃ is absent, p3 is 2, and p2 is 0.

In one embodiment, p1 is 5, Z₃ is absent, p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 5, Z₃ is absent, p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p1 is 1 and Z₃ is C(O).

In one embodiment, p1 is 1, Z₃ is C(O), and p3 is 2.

15 In one embodiment, p1 is 1, Z₃ is C(O), and p2 is 0.

In one embodiment, p1 is 1, Z₃ is C(O), p3 is 2, and p2 is 0.

In one embodiment, p1 is 1, Z₃ is C(O), p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 1, Z₃ is C(O), p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p1 is 3 and Z₃ is C(O).

20 In one embodiment, p1 is 3, Z₃ is C(O), and p3 is 2.

In one embodiment, p1 is 3, Z₃ is C(O), and p2 is 0.

In one embodiment, p1 is 3, Z₃ is C(O), p3 is 2, and p2 is 0.

In one embodiment, p1 is 3, Z₃ is C(O), p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 3, Z₃ is C(O), p3 is 2, p2 is 0, each W is O, and Q is absent.

25 In one embodiment, p1 is 5 and Z₃ is C(O).

In one embodiment, p1 is 5, Z₃ is C(O), and p3 is 2.

In one embodiment, p1 is 5, Z₃ is C(O), and p2 is 0.

In one embodiment, p1 is 5, Z₃ is C(O), p3 is 2, and p2 is 0.

In one embodiment, p1 is 5, Z₃ is C(O), p3 is 2, p2 is 0, and each W is O.

30 In one embodiment, p1 is 5, Z₃ is C(O), p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p2 is 0 and Q is absent.

- In one embodiment, p2 is 0; Q is absent; and each W is O.
- In one embodiment, p2 is 0; Q is absent; and p1 is 2-4.
- In one embodiment, p2 is 0; Q is absent; and p1 is 2.
- In one embodiment, p2 is 0; Q is absent; and p1 is 4.
- 5 In one embodiment, p2 is 0; Q is absent; and p3 is 2.
- In one embodiment, p2 is 0; Q is absent; and Z₃ is C(O).
- In one embodiment, p2 is 0; Q is absent; each W is O; and p1 is 2-4.
- In one embodiment, p2 is 0; Q is absent; each W is O; and p1 is 2.
- In one embodiment, p2 is 0; Q is absent; each W is O; and p1 is 4.
- 10 In one embodiment, p2 is 0; Q is absent; each W is O; and p3 is 2.
- In one embodiment, p2 is 0; Q is absent; each W is O; and Z₃ is C(O).
- In one embodiment, p2 is 0; Q is absent; each W is O; p3 is 2; and Z₃ is C(O).
- In one embodiment, p3 is 3 and Z₃ is absent.
- In one embodiment, p3 is 3, Z₃ is absent, and p1 is 0.
- 15 In one embodiment, p3 is 3, Z₃ is absent, p1 is 0, and Q is absent.
- In one embodiment, p3 is 4 and Z₃ is absent.
- In one embodiment, p3 is 4, Z₃ is absent, and p1 is 0.
- In one embodiment, p3 is 4, Z₃ is absent, p1 is 0, and Q is absent.
- In one embodiment, p3 is 2, and Z₃ is absent.
- 20 In one embodiment, p1 is 3 and Z₃ is (CH₂)_jC(O)NH.
- In one embodiment, p1 is 3 and Z₃ is (CH₂)C(O)NH.
- In one embodiment, p1 is 3 and Z₃ is (CH₂)₂C(O)NH.
- In one embodiment, p1 is 3 and Z₃ is (CH₂)₃C(O)NH.
- In one embodiment, p1 is 3, Z₃ is (CH₂)_jC(O)NH, and p3 is 2.
- 25 In one embodiment, p1 is 3, Z₃ is (CH₂)C(O)NH, and p3 is 2.
- In one embodiment, p1 is 3, Z₃ is (CH₂)₂C(O)NH, and p3 is 2.
- In one embodiment, p1 is 3, Z₃ is (CH₂)₃C(O)NH, and p3 is 2.
- In one embodiment, p1 is 3, Z₃ is (CH₂)_jC(O)NH, p3 is 2, and p2 is 0.
- In one embodiment, p1 is 3, Z₃ is (CH₂)C(O)NH, p3 is 2, and p2 is 0.
- 30 In one embodiment, p1 is 3, Z₃ is (CH₂)₂C(O)NH, p3 is 2, and p2 is 0.
- In one embodiment, p1 is 3, Z₃ is (CH₂)₃C(O)NH, p3 is 2, and p2 is 0.

In one embodiment, p1 is 3, Z₃ is (CH₂)₂C(O)NH, p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 3, Z₃ is (CH₂)C(O)NH, p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 3, Z₃ is (CH₂)₂C(O)NH, p3 is 2, p2 is 0, and each W is O.

In one embodiment, p1 is 3, Z₃ is (CH₂)₃C(O)NH, p3 is 2, p2 is 0, and each W is O.

5 In one embodiment, p1 is 3, Z₃ is (CH₂)₂C(O)NH, p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p1 is 3, Z₃ is (CH₂)C(O)NH, p3 is 2, p2 is 0, each W is O, and Q is absent.

10 In one embodiment, p1 is 3, Z₃ is (CH₂)₂C(O)NH, p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p1 is 3, Z₃ is (CH₂)₃C(O)NH, p3 is 2, p2 is 0, each W is O, and Q is absent.

In one embodiment, p1 is 3 and Z₃ is CH₂C(O)NH.

In one embodiment, p1 is 3, Z₃ is CH₂C(O)NH, and Q is absent.

15 In one embodiment, p1 is 4 and Z₃ is absent.

In one embodiment, p1 is 4, Z₃ is absent, and p2 is 1.

In one embodiment, p1 is 4, Z₃ is absent, p2 is 1, and Q is absent.

In one embodiment, p1 is 4, Z₃ is absent, p2 is 1, and p3 is 3.

In one embodiment, p1 is 4, Z₃ is absent, p2 is 1, p3 is 3, and Q is absent.

20 In one embodiment, p1 is 3 and Z₃ is absent.

In one embodiment, p1 is 3, Z₃ is absent, and p3 is 3.

In one embodiment, p1 is 3, Q is absent, and p3 is 3.

In one embodiment, p1 is 4, Z₃ is absent, and p3 is 3.

In one embodiment, p1 is 4, Z₃ is absent, p3 is 3, and Q is absent.

25 In one embodiment, p1 is 4, Z₃ is absent, p3 is 3, Q is absent, and p2 is 0.

In one embodiment, p1 is 4, Z₃ is absent, and Q is absent.

In one embodiment, p1 is 3, Z₃ is CH₂C(O)NH, and Q is absent.

In one embodiment, p1 is 3, Z₃ is CH₂C(O)NH, Q is absent, and p3 is 2.

In one embodiment, p1 is 4, Q is absent, and p3 is 1.

30 In one embodiment, p1 is 4, Q is absent, p3 is 1, and p2 is 0.

In one embodiment, p1 is 4, Q is absent, and p3 is 3.


Degron is of any one of Formulae D1a-D1f', and the Linker is selected from L1 – L7. In one embodiment, the Degron is of any one of Formulae D1g-D11', and the Linker is selected from L1 – L7. In one embodiment, the Degron is of any one of Formulae D1a-D1f', and the Linker is L1, L2, or L3. In one embodiment, the Degron is of any one of Formulae D1g-D11', and the Linker is L1, L2, or L3. In one embodiment, the Degron is of any one of Formulae D1a-D1f', and the Linker is L4, L5, L6, or L7. In one embodiment, the Degron is of any one of Formulae D1g-D11', and the Linker is L4, L5, L6, or L7. In one embodiment, the Degron is of Formula D1a or D1a', and the Linker is L1, L2, or L3. In one embodiment, the Degron is of Formula D1g or D1g', and the Linker is L1, L2, or L3. In one embodiment, the Degron is of Formula D1a or D1a', and the Linker is L4, L5, L6, or L7. In one embodiment, the Degron is of Formula D1g or D1g', and the Linker is L4, L5, L6, or L7. In one embodiment, the Degron is of Formula D1a or D1a', and the Linker is L2. In one embodiment, the Degron is of Formula D1g or D1g', and the Linker is L2.





In one embodiment, the Linker is designed and optimized based on SAR (structure-activity relationship) and X-ray crystallography of the Targeting Ligand with regard to the location of attachment for the Linker.

In one embodiment, the optimal Linker length and composition vary by the Targeting Ligand and can be estimated based upon X-ray structure of the Targeting Ligand bound to its target. Linker length and composition can be also modified to modulate metabolic stability and pharmacokinetic (PK) and pharmacodynamics (PD) parameters.

Some embodiments of present application relate to the bifunctional compounds having the following structures in Table A:

Table A

Cmpd No.	Structure
I-1	

Cmpd No.	Structure
I-2	
I-3	
I-4	
I-5	

Some of the foregoing compounds can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, *e.g.*, stereoisomers and/or diastereomers. Accordingly, compounds of the application may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers. In one embodiment, the

compounds of the application are enantiopure compounds. In another embodiment, mixtures of stereoisomers or diastereomers are provided.

Furthermore, certain compounds, as described herein, may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated. The application additionally encompasses the compounds as individual Z/E isomers substantially free of other E/Z isomers and alternatively, as mixtures of various isomers.

In one embodiment, the present application relates to compounds that target proteins, such as CDK8 and/or CDK19 for degradation, which have numerous advantages over inhibitors of protein function (*e.g.*, kinase activity) and can a) overcome resistance in certain cases; b) prolong the kinetics of drug effect by destroying the protein, thus requiring resynthesis of the protein even after the compound has been metabolized; c) target all functions of a protein at once rather than a specific catalytic activity or binding event; d) expand the number of drug targets by including all proteins that a ligand can be developed for, rather than proteins whose activity (*e.g.*, kinase activity) can be affected by a small molecule inhibitor, antagonist or agonist; and e) have increased potency compared to inhibitors due to the possibility of the small molecule acting catalytically.

Some embodiments of the present application relate to degradation or loss of 30% to 100% of the target protein. Some embodiments relate to the loss of 50-100% of the target protein. Other embodiments relate to the loss of 75-95% of the targeted protein.

A bifunctional compound of the present application (*e.g.*, a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is capable of modulating (*e.g.*, decreasing) the amount of a targeted protein (*e.g.*, CDK8 and/or CDK19). A bifunctional compound of the present application (*e.g.*, a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is also capable of degrading a targeted protein (*e.g.*, CDK8 and/or CDK19) through the UPP pathway. Accordingly, a bifunctional compound of the present application (*e.g.*, a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is capable of treating or preventing a disease or disorder in which CDK8 and/or CDK19 plays a role. A bifunctional compound of the present application (*e.g.*, a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is also capable of treating or preventing a

disease or disorder in which CDK8 and/or CDK19 plays a role or in which CDK8 and/or CDK19 is deregulated (*e.g.*, overexpressed).

Modulation of CDK8 and/or CDK19 through UPP-mediated degradation by a bifunctional compound of the application, such as those described herein, provides a novel
5 approach to the treatment, prevention, or amelioration of diseases or disorders in which CDK8 and/or CDK19 plays a role including, but not limited to, cancer and metastasis, inflammation, arthritis, systemic lupus erthematosus, skin-related disorders, pulmonary disorders, cardiovascular disease, ischemia, neurodegenerative disorders, liver disease, gastrointestinal disorders, viral and bacterial infections, central nervous system disorders, Alzheimer's disease,
10 Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and peripheral neuropathy. Further, modulation of CDK8 and/or CDK19 through UPP-mediated degradation by a bifunctional compound of the application, such as those described herein, also provides a new paradigm for treating, preventing, or ameliorating diseases or disorders in which CDK8 and/or CDK19 is deregulated.

15 In one embodiment, a bifunctional compound of the present application (*e.g.*, a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is more efficacious in treating a disease or condition (*e.g.*, cancer) than, or is capable of treating a disease or condition resistant to, the Targeting Ligand, when the Targeting Ligand is administered alone (*i.e.*, not bonded to a Linker and a
20 Degron). In one embodiment, a bifunctional compound of the present application (*e.g.*, a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is capable of modulating (*e.g.*, decreasing) the amount of CDK8 and/or CDK19, and thus is useful in treating a disease or condition (*e.g.*, cancer) in which CDK8 and/or CDK19 plays a role.

25 In one embodiment, the bifunctional compound of the present application that is more efficacious in treating a disease or condition than, or is capable of treating a disease or condition resistant to, the Targeting Ligand, when the Targeting Ligand is administered alone (*i.e.*, not bonded to a Linker and a Degron), is more potent in inhibiting the growth of cells (*e.g.*, cancer cells) or decreasing the viability of cells (*e.g.*, cancer cells), than the Targeting Ligand, when the
30 Targeting Ligand is administered alone (*i.e.*, not bonded to a Linker and a Degron). In one embodiment, the bifunctional compound inhibits the growth of cells (*e.g.*, cancer cells) or

decreases the viability of cells (*e.g.*, cancer cells) at an IC_{50} that is lower than the IC_{50} of the Targeting Ligand (when the Targeting Ligand is administered alone (*i.e.*, not bonded to a Linker and a Degron)) for inhibiting the growth or decreasing the viability of the cells. In one embodiment, the IC_{50} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the IC_{50} of the bifunctional compound is at most 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the IC_{50} of the bifunctional compound is at most 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the IC_{50} of the bifunctional compound is at most 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the IC_{50} of the bifunctional compound is at most 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the IC_{50} of the bifunctional compound is at most 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the IC_{50} of the bifunctional compound is at most 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC_{50} of the Targeting Ligand. In one embodiment, the bifunctional compound inhibits the growth of cells (*e.g.*, cancer cells) or decreases the viability of cells (*e.g.*, cancer cells) at an E_{max} that is lower than the E_{max} of the Targeting Ligand (when the Targeting Ligand is administered alone (*i.e.*, not bonded to a Linker and a Degron)) for inhibiting the growth or decreasing the viability of the cells. In one embodiment, the E_{max} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, or 1% of the E_{max} of the Targeting Ligand. In one embodiment, the E_{max} of the bifunctional compound is at most 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, or 1% of the E_{max} of the Targeting Ligand. In one embodiment, the E_{max} of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the E_{max} of the Targeting Ligand.

In some embodiments, the inhibition or degradation of CDK8 and/or CDK19 activity is measured by IC_{50} .

In some embodiments, the inhibition or degradation of CDK8 and/or CDK19 activity is measured by EC_{50} .

Potency of the inhibitor or degrader can be determined by EC_{50} value. A compound with a lower EC_{50} value, as determined under substantially similar conditions, is a more potent inhibitor or degrader relative to a compound with a higher EC_{50} value. In some embodiments, the substantially similar conditions comprise determining a CDK8- and/or CDK19-dependent phosphorylation level, *in vitro* or *in vivo* (e.g., in cells expressing a wild-type CDK8 and/or CDK19, a mutant CDK8 and/or CDK19, or a fragment of any thereof).

Potency of the inhibitor or degrader can also be determined by IC_{50} value. A compound with a lower IC_{50} value, as determined under substantially similar conditions, is a more potent inhibitor or degrader relative to a compound with a higher IC_{50} value. In some embodiments, the substantially similar conditions comprise determining a CDK8- and/or CDK19-dependent phosphorylation level, *in vitro* or *in vivo* (e.g., in cells expressing a wild-type CDK8 and/or CDK19, a mutant CDK8 and/or CDK19, or a fragment of any thereof).

In one embodiment, the bifunctional compounds of the present application are useful as anticancer agents, and thus may be useful in the treatment of cancer, by effecting tumor cell death or inhibiting the growth of tumor cells. In certain exemplary embodiments, the disclosed anticancer agents are useful in the treatment of cancers and other proliferative disorders, including, but not limited to breast cancer, cervical cancer, colon and rectal cancer, leukemia, lung cancer (e.g., non-small cell lung cancer), melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, leukemias (e.g., myeloid, lymphocytic, myelocytic and lymphoblastic leukemias), malignant melanomas, and T-cell lymphoma.

A "selective CDK8 inhibitor or degrader" or "selective CDK19 inhibitor or degrader," can be identified, for example, by comparing the ability of a compound to inhibit the kinase activity of or degrade CDK8 or CDK19 to its ability to inhibit or degrade the other members of the CDK kinase family or other kinases. For example, a substance may be assayed for its ability to inhibit CDK8 kinase activity or degrade CDK8, as well as CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK11, CDK12, CDK13, CDK14 and other kinases. In some embodiments, the selectivity can be identified by measuring the EC_{50} or IC_{50} of the compounds.

In some embodiments, the bifunctional compounds of the present application containing a Target Ligand inhibit or degrade CDK8 and/or CDK19 more selectively over other cyclin-dependent kinases and/or other kinases than the Target Ligand alone (*i.e.*, a Target Ligand itself

compared to the Target Ligand covalently bound to a Linker and a Degron). In certain
embodiments, the bifunctional compounds of the application are about 10%, about 20%, about
30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 99% more
selective at inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand alone. In
5 certain embodiments, the bifunctional compounds of the application are about 10%, about 20%,
about 30%, about 40%, or about 50% more selective at inhibiting or degrading CDK8 and/or
CDK19 than the Target Ligand alone. In certain embodiments, the bifunctional compounds of
the application are about 20%, about 30%, about 40%, about 50% or about 60% more selective
at inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand alone. In certain
10 embodiments, the bifunctional compounds of the application are about 30%, about 40%, about
50%, about 60% or about 70% more selective at inhibiting or degrading CDK8 and/or CDK19
than the Target Ligand alone. In certain embodiments, the bifunctional compounds of the
application are about 40%, about 50%, about 60%, about 70%, or about 80% more selective at
inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand alone. In certain
15 embodiments, the bifunctional compounds of the application are about 50%, about 60%, about
70%, about 80%, or about 90% more selective at inhibiting or degrading CDK8 and/or CDK19
than the Target Ligand alone. In certain embodiments, the bifunctional compounds of the
application are about 60%, about 70%, about 80%, about 90%, or about 99% more selective at
inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand alone. In other
20 embodiments, the bifunctional compounds of the application are at least 10%, at least 20%, at
least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at
least 99% more selective at inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand
alone.

In other embodiments, the bifunctional compounds of the application are between about
25 10% and about 99% more selective at inhibiting or degrading CDK8 and/or CDK19 than the
Target Ligand alone. In other embodiments, the bifunctional compounds of the application are
between about 10% and about 30% more selective at inhibiting or degrading CDK8 and/or
CDK19 than the Target Ligand alone. In other embodiments, the bifunctional compounds of the
application are between about 20% and about 40% more selective at inhibiting or degrading
30 CDK8 and/or CDK19 than the Target Ligand alone. In other embodiments, the bifunctional
compounds of the application are between about 30% and about 50% more selective at inhibiting

or degrading CDK8 and/or CDK19 than the Target Ligand alone. In other embodiments, the bifunctional compounds of the application are between about 40% and about 60% more selective at inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand alone. In other
5 embodiments, the bifunctional compounds of the application are between about 50% and about 70% more selective at inhibiting or degrading CDK8 and/or CDK19 than the Target Ligand alone. In other embodiments, the bifunctional compounds of the application are between about 60% and about 80% more selective at inhibiting or degrading CDK8 and/or CDK19 than the
10 Target Ligand alone. In other embodiments, the bifunctional compounds of the application are between about 70% and about 90% more selective at inhibiting or degrading CDK8 and/or
10 CDK19 than the Target Ligand alone. In other embodiments, the bifunctional compounds of the application are between about 80% and about 99% more selective at inhibiting or degrading
CDK8 and/or CDK19 than the Target Ligand alone.

In some embodiments, the compounds of the present application are selective over other kinases. As used herein, “selective”, “selective CDK8 inhibitor,” “selective CDK19 inhibitor,”
15 “selective CDK8 degrader,” “selective CDK19 degrader,” “selective CDK8 compound,” or
“selective CDK19 compound” refers to a compound, for example a bifunctional compound of the application, that effectively inhibits or degrades CDK8 and/or CDK19 kinase to a greater
extent than any other kinase enzyme, particularly any enzyme from the Cyclic-dependent kinase family (*e.g.*, CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK11, CDK12, CDK13, CDK14,
20 *etc.*)

In certain embodiments, the compounds of the application are CDK8 and/or CDK19 inhibitors or degraders that exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold or 100-
fold selectivity over other kinases (*e.g.*, CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK11, CDK12, CDK13, CDK14, *etc.*). In various embodiments, the compounds of the application
25 exhibit 1000-fold selectivity over other kinases.

In certain embodiments, the compounds of the application are CDK8 and/or CDK19 inhibitors or degraders that exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold or 100-
fold selectivity over other cyclin-dependent kinases (*e.g.*, CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK11, CDK12, CDK13, CDK14, *etc.*). In various embodiments, the compounds of the
30 application exhibit 1000-fold selectivity over other cyclin-dependent kinases.

Definitions

Listed below are definitions of various terms used in this application. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

5 The term "alkyl," as used herein, refers to saturated, straight or branched-chain hydrocarbon radicals containing, in certain embodiments, between one and six carbon atoms. Examples of C₁-C₆ alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, and n-hexyl radicals.

10 The term "alkenyl," as used herein, denotes a monovalent group derived from a hydrocarbon moiety containing, in certain embodiments, from two to six carbon atoms having at least one carbon-carbon double bond. The double bond may or may not be the point of attachment to another group. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl and the like.

 The term "alkoxy" refers to an -O-alkyl radical.

15 The terms "hal," "halo," and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.

 The term "aryl," as used herein, refers to a mono- or poly-cyclic carbocyclic ring system having one or more aromatic rings, fused or non-fused, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like.

20 The term "aralkyl," as used herein, refers to an alkyl residue attached to an aryl ring. Examples include, but are not limited to, benzyl, phenethyl and the like.

 The term "cycloalkyl," as used herein, denotes a monovalent group derived from a monocyclic or polycyclic saturated or partially unsaturated carbocyclic ring compound. Examples of C₃-C₈ cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; and examples of C₃-C₁₂-cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl. Also contemplated is a monovalent group derived from a monocyclic or polycyclic carbocyclic ring compound having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Examples of such groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like.

30

The term "heteroaryl," as used herein, refers to a mono- or poly-cyclic (*e.g.*, bi-, or tri-cyclic or more) fused or non-fused, radical or ring system having at least one aromatic ring, having from five to ten ring atoms of which one ring atoms is selected from S, O, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxaliny, and the like.

The term "heteroaralkyl," as used herein, refers to an alkyl residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.

The term "heterocyclyl," or "heterocycloalkyl," as used herein, refers to a non-aromatic 3-, 4-, 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused of non-fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, and (iv) the nitrogen heteroatom may optionally be quaternized. Representative heterocycloalkyl groups include, but are not limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazoliny, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.

The term "alkylamino" refers to a group having the structure $\text{-NH}(\text{C}_1\text{-C}_{12} \text{ alkyl})$, *e.g.*, $\text{-NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, where $\text{C}_1\text{-C}_{12} \text{ alkyl}$ is as previously defined.

The term "dialkylamino" refers to a group having the structure $\text{-N}(\text{C}_1\text{-C}_{12} \text{ alkyl})_2$, *e.g.*, $\text{-NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, where $\text{C}_1\text{-C}_{12} \text{ alkyl}$ is as previously defined.

The term "acyl" includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates. Examples of aliphatic carbonyls include, but are not limited to, acetyl, propionyl, 2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like.

In accordance with the application, any of the aryls, substituted aryls, heteroaryls and substituted heteroaryls described herein, can be any aromatic group. Aromatic groups can be substituted or unsubstituted.

As described herein, compounds of the application and moieties present in the compounds
 5 may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the application. It will be appreciated that the phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." In general, the term "substituted", whether preceded by the term "optionally" or not, refers to the replacement of hydrogen radicals in a given structure with the
 10 radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. The terms "optionally substituted", "optionally substituted alkyl", "optionally substituted "optionally substituted alkenyl", "optionally substituted alkynyl", "optionally substituted cycloalkyl,"
 15 "optionally substituted cycloalkenyl," "optionally substituted aryl", "optionally substituted heteroaryl," "optionally substituted aralkyl", "optionally substituted heteroaralkyl," "optionally substituted heterocycloalkyl," and any other optionally substituted group as used herein, refer to groups that are substituted or unsubstituted by independent replacement of one, two, or three or
 20 more of the hydrogen atoms thereon with substituents including, but not limited to:

-F, -Cl, -Br, -I, -OH, protected hydroxy, -NO₂, -CN, -NH₂, protected amino, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₁₂-alkenyl, -NH-C₂-C₁₂-alkenyl, -NH-C₃-C₁₂-cycloalkyl,
 -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -dialkylamino, -diarylamino,
 -diheteroarylamino, -O-C₁-C₁₂-alkyl, -O-C₂-C₁₂-alkenyl, -O-C₂-C₁₂-alkenyl,
 25 -O-C₃-C₁₂-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycloalkyl, -C(O)-C₁-C₁₂-alkyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₂-C₁₂-alkenyl, -C(O)-C₃-C₁₂-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH₂, -CONH-C₁-C₁₂-alkyl, -CONH-C₂-C₁₂-alkenyl,
 -CONH-C₂-C₁₂-alkenyl, -CONH-C₃-C₁₂-cycloalkyl, -CONH-aryl, -CONH-heteroaryl,
 -CONH-heterocycloalkyl, -OCO₂-C₁-C₁₂-alkyl, -OCO₂-C₂-C₁₂-alkenyl, -OCO₂-C₂-C₁₂-alkenyl,
 30 -OCO₂-C₃-C₁₂-cycloalkyl, -OCO₂-aryl, -OCO₂-heteroaryl, -OCO₂-heterocycloalkyl, -OCONH₂, -OCONH-C₁-C₁₂-alkyl, -OCONH-C₂-C₁₂-alkenyl, -OCONH-C₂-C₁₂-alkenyl,

- OCONH-C₃-C₁₂-cycloalkyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocycloalkyl,
 -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₁₂-alkenyl, -NHC(O)-C₂-C₁₂-alkenyl,
 -NHC(O)-C₃-C₁₂-cycloalkyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl,
 -NHCO₂-C₁-C₁₂-alkyl, -NHCO₂-C₂-C₁₂-alkenyl, -NHCO₂-C₂-C₁₂-alkenyl,
 5 -NHCO₂-C₃-C₁₂-cycloalkyl, -NHCO₂-aryl, -NHCO₂-heteroaryl, -NHCO₂-heterocycloalkyl,
 NHC(O)NH₂, -NHC(O)NH-C₁-C₁₂-alkyl, -NHC(O)NH-C₂-C₁₂-alkenyl,
 -NHC(O)NH-C₂-C₁₂-alkenyl, -NHC(O)NH-C₃-C₁₂-cycloalkyl, -NHC(O)NH-aryl,
 -NHC(O)NH-heteroaryl, NHC(O)NH-heterocycloalkyl, -NHC(S)NH₂,
 -NHC(S)NH-C₁-C₁₂-alkyl, -NHC(S)NH-C₂-C₁₂-alkenyl,
 10 -NHC(S)NH-C₂-C₁₂-alkenyl, -NHC(S)NH-C₃-C₁₂-cycloalkyl, -NHC(S)NH-aryl,
 -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH₂,
 -NHC(NH)NH-C₁-C₁₂-alkyl, -NHC(NH)NH-C₂-C₁₂-alkenyl, -NHC(NH)NH-C₂-C₁₂-alkenyl,
 -NHC(NH)NH-C₃-C₁₂-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl,
 -NHC(NH)NHheterocycloalkyl, -NHC(NH)-C₁-C₁₂-alkyl, -NHC(NH)-C₂-C₁₂-alkenyl,
 15 -NHC(NH)-C₂-C₁₂-alkenyl, -NHC(NH)-C₃-C₁₂-cycloalkyl, -NHC(NH)-aryl,
 -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C₁-C₁₂-alkyl,
 -C(NH)NH-C₂-C₁₂-alkenyl, -C(NH)NH-C₂-C₁₂-alkenyl, C(NH)NH-C₃-C₁₂-cycloalkyl,
 -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NHheterocycloalkyl,
 -S(O)-C₁-C₁₂-alkyl, -S(O)-C₂-C₁₂-alkenyl, -S(O)-C₂-C₁₂-alkenyl,
 20 -S(O)-C₃-C₁₂-cycloalkyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocycloalkyl -SO₂NH₂,
 -SO₂NH-C₁-C₁₂-alkyl, -SO₂NH-C₂-C₁₂-alkenyl, -SO₂NH-C₂-C₁₂-alkenyl,
 -SO₂NH-C₃-C₁₂-cycloalkyl, -SO₂NH-aryl, -SO₂NH-heteroaryl, -SO₂NH-heterocycloalkyl,
 -NHSO₂-C₁-C₁₂-alkyl, -NHSO₂-C₂-C₁₂-alkenyl, -NHSO₂-C₂-C₁₂-alkenyl,
 -NHSO₂-C₃-C₁₂-cycloalkyl, -NHSO₂-aryl, -NHSO₂-heteroaryl, -NHSO₂-heterocycloalkyl,
 25 -CH₂NH₂, -CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl,
 -C₃-C₁₂-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, -SH,
 -S-C₁-C₁₂-alkyl, -S-C₂-C₁₂-alkenyl, -S-C₂-C₁₂-alkenyl, -S-C₃-C₁₂-cycloalkyl, -S-aryl,
 -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl.

It is understood that the aryls, heteroaryls, alkyls, and the like can be substituted.

- 30 The term "cancer" includes, but is not limited to, the following cancers: epidermoid oral:
 buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma,

rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma;
 Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell,
 undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
 adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal:
 5 esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma),
 stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma,
 insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small
 intestines (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma,
 hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma,
 10 tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal,
 rectum; Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma),
 lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell
 carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma,
 embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma,
 15 fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular
 carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma,
 hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma,
 malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma
 (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma,
 20 osteochondroma (osteochondromatous exostoses), benign chondroma, chondroblastoma,
 chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma,
 hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma,
 meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma,
 germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma,
 25 retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma);
 Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical
 dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous
 cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell
 tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial
 30 carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous
 cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma),

breast; Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma) hairy cell; lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, undifferentiated thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above-identified conditions.

The term "CDK8" herein refers to cyclin-dependent kinase 8.

The term "CDK19" herein refers to cyclin-dependent kinase 19.

The term "subject" as used herein refers to a mammal. A subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like. Preferably the subject is a human. When the subject is a human, the subject may be referred to herein as a patient.

"Treat", "treating" and "treatment" refer to a method of alleviating or abating a disease and/or its attendant symptoms.

As used herein, "preventing" or "prevent" describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.

The term "targeted protein(s)" is used interchangeably with "target protein(s)", unless the context clearly dictates otherwise. In one embodiment, a "targeted protein" is CDK.

The term "subject" as used herein refers to a mammal. A subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like. Preferably the subject is a human. When the subject is a human, the subject may be referred to herein as a patient.

The terms "disease(s)", "disorder(s)", and "condition(s)" are used interchangeably, unless the context clearly dictates otherwise.

The term "therapeutically effective amount" of a bifunctional compound or pharmaceutical composition of the application, as used herein, means a sufficient amount of the bifunctional compound or pharmaceutical composition so as to decrease the symptoms of a disorder in a subject. As is well understood in the medical arts a therapeutically effective amount

of a bifunctional compound or pharmaceutical composition of this application will be at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present application will be decided by the attending physician within the scope of sound medical judgment. The specific
5 inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or
10 coincidental with the specific compound employed; and like factors well known in the medical arts.

As used herein, the term "pharmaceutically acceptable salt" refers to those salts of the compounds formed by the process of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals
15 without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, *et al.* describes pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the application, or separately by reacting the free
20 base or acid function with a suitable acid or base.

Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts: salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Other pharmaceutically
25 acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate,
30 malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate,

propionate, stearate, succinate, sulfate, tartrate, thiocyanate, /7-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations
5 formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

As used herein, the term "pharmaceutically acceptable ester" refers to esters of the bifunctional compounds formed by the process of the present application which hydrolyze *in vivo* and include those that break down readily in the human body to leave the parent compound or a
10 salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic, alkenolic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

15 The term "pharmaceutically acceptable prodrugs" as used herein, refers to those prodrugs of the bifunctional compounds formed by the process of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as
20 the zwitterionic forms, where possible, of the compounds of the present application. "Prodrug", as used herein, means a compound which is convertible *in vivo* by metabolic means (*e.g.*, by hydrolysis) to afford any compound delineated by the formulae of the instant application. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, *et al.* (ed.), Methods in Enzymology, vol. 4,
25 Academic Press (1985); Krogsgaard-Larsen, *et al.*, (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, *et al.*, Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, "Hydrolysis In Drug
30 And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology," John Wiley and Sons, Ltd. (2002).

This application also encompasses pharmaceutical compositions containing, and methods of treating disorders through administering, pharmaceutically acceptable prodrugs of bifunctional compounds of the application. For example, compounds of the application having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (*e.g.*, two, 5 three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the application. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemossine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, 10 homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxy carbonyls, as outlined in *Advanced Drug Delivery Reviews*, 1996, 19, 1 15. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the 20 acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in *J. Med. Chem.* 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphoramides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.

The application also provides for a pharmaceutical composition comprising a 25 therapeutically effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In another aspect, the application provides a kit comprising a bifunctional compound capable of inhibiting the activity of or degrading CDK8 and/or CDK19 selected from one or 30 more compounds disclosed herein, or an enantiomer, diastereomer, stereoisomer, or

pharmaceutically acceptable salt thereof, optionally in combination with a second agent and instructions for use in treating cancer.

In another aspect, the application provides a method of synthesizing a bifunctional compound disclosed herein.

5 The synthesis of the bifunctional compounds of the application can be found herein and in the Examples below.

Other embodiments are a method of making a bifunctional compound of any of the formulae herein using any one, or combination of, reactions delineated herein. The method can include the use of one or more intermediates or chemical reagents delineated herein.

10 Another aspect is an isotopically labeled bifunctional compound of any of the formulae delineated herein. Such compounds have one or more isotope atoms which may or may not be radioactive (*e.g.*, ^3H , ^2H , ^{14}C , ^{13}C , ^{18}F , ^{35}S , ^{32}P , ^{125}I , and ^{131}I) introduced into the bifunctional compound. Such compounds are useful for drug metabolism studies and diagnostics, as well as therapeutic applications.

15 A bifunctional compound of the application can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a bifunctional compound of the application can be prepared by reacting the free acid form of the bifunctional compound with a pharmaceutically acceptable
20 inorganic or organic base.

Alternatively, the salt forms of the bifunctional compounds of the application can be prepared using salts of the starting materials or intermediates.

The free acid or free base forms of the bifunctional compounds of the application can be prepared from the corresponding base addition salt or acid addition salt form, respectively. For
25 example, a bifunctional compound of the application in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (*e.g.*, ammonium hydroxide solution, sodium hydroxide, and the like). A bifunctional compound of the application in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (*e.g.*, hydrochloric acid, *etc.*).

30 Prodrugs of the bifunctional compounds of the application can be prepared by methods known to those of ordinary skill in the art (*e.g.*, for further details see Saulnier *et al.*, (1994),

Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized bifunctional compound of the application with a suitable carbamylating agent (*e.g.*, 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).

5 Protected derivatives of the bifunctional compounds of the application can be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc., 1999.

 Compounds of the present application can be conveniently prepared, or formed during the
10 process of the application, as solvates (*e.g.*, hydrates). Hydrates of bifunctional compounds of the present application can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

 Acids and bases useful in the methods herein are known in the art. Acid catalysts are any
15 acidic chemical, which can be inorganic (*e.g.*, hydrochloric, sulfuric, nitric acids, aluminum trichloride) or organic (*e.g.*, camphorsulfonic acid, p-toluenesulfonic acid, acetic acid, ytterbium triflate) in nature. Acids are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions. Bases are any basic chemical, which can be inorganic (*e.g.*, sodium bicarbonate, potassium hydroxide) or organic (*e.g.*, triethylamine, pyridine) in nature. Bases are
20 useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.

 Combinations of substituents and variables envisioned by this application are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed
25 herein (*e.g.*, therapeutic or prophylactic administration to a subject).

 When any variable (*e.g.*, R₁₄) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with one or more R₁₄ moieties, then R₁₄ at each occurrence is selected independently from the definition of R₁₄. Also,
30 combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds within a designated atom's normal valency.

In addition, some of the compounds of this application have one or more double bonds, or one or more asymmetric centers. Such compounds can occur as racemates, racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans- or *E*- or *Z*- double isomeric forms, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both *E* and *Z* geometric isomers. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond depicted arbitrarily herein as *trans* may be *cis*, *trans*, or a mixture of the two in any proportion. All such isomeric forms of such compounds are expressly included in the present application.

Optical isomers may be prepared from their respective optically active precursors by the procedures described herein, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, *et al.*, *Enantiomers, Racemates, and Resolutions* (John Wiley & Sons, 1981).

“Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture”.

A carbon atom bonded to four non-identical substituents is termed a “chiral center”.

“Chiral isomer” means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture”. When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the

chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the *Sequence Rule* of Cahn, Ingold and Prelog. (Cahn *et al.*, *Angew. Chem. Inter. Edit.* 1966, 5, 385; errata 511; Cahn *et al.*, *Angew. Chem.* 1966, 78, 413; Cahn and Ingold, *J. Chem. Soc.* 1951 (London), 612; Cahn *et al.*, *Experientia* 1956, 12, 81; Cahn, *J. Chem. Educ.* 1964, 41, 116).

“Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes *cis* and *trans*, or *Z* and *E*, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

Furthermore, the structures and other compounds discussed in this application include all atropic isomers thereof. “Atropic isomers” are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques; it has been possible to separate mixtures of two atropic isomers in select cases.

“Tautomer” is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerizations is called tautomerism.

Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose. Common tautomeric pairs are: ketone-enol, amide-nitrile, lactam-lactim, amide-imidic acid tautomerism in heterocyclic rings (*e.g.*, in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine. The compounds of this application may also be represented in multiple tautomeric forms, in such instances, the

application expressly includes all tautomeric forms of the compounds described herein (*e.g.*, alkylation of a ring system may result in alkylation at multiple sites, the application expressly includes all such reaction products).

In the present application, the structural formula of the bifunctional compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like. In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like.

Additionally, the compounds of the present application, for example, the salts of the bifunctional compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, *etc.* Non-limiting examples of solvates include ethanol solvates, acetone solvates, *etc.*

“Solvate” means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H₂O.

The synthesized bifunctional compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the bifunctional compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. In addition, the solvents, temperatures, reaction durations, *etc.* delineated herein are for purposes of illustration only and one of ordinary skill in the art will recognize that variation of the reaction conditions can produce the desired bridged macrocyclic products of the present application. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in

synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995), and subsequent editions thereof.

The compounds of this application may be modified by appending various functionalities via any synthetic means delineated herein to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The compounds of the application are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.

The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

Method of Synthesizing the Compounds

Compounds of the present application can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 5th edition, John Wiley & Sons: New York, 2001; and Greene, T.W., Wuts, P.G. M., *Protective Groups in Organic Synthesis*, 3rd edition, John Wiley &


Sons: New York, 1999, are useful and recognized reference textbooks of organic synthesis known to those in the art. The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of compounds of the present application. The processes generally provide the desired final
5 compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester or prodrug thereof. Suitable synthetic routes are depicted in the schemes below.

Those skilled in the art will recognize if a stereocenter exists in the compounds disclosed herein. Accordingly, the present application includes both possible stereoisomers (unless
10 specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example,
15 "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).

The compounds of the present application can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present application can be synthesized using the methods described below, together with
20 synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below.

Compounds of the present application can be synthesized by following the steps outlined in General Schemes 1-4 which comprise different sequences of assembling intermediates.
25 Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated.

Targeting Ligands of the present application can be synthesized by following the steps outlined in General Schemes 5 and 6 which comprise different sequences of assembling intermediates. Starting materials are either commercially available or made by known
30 procedures in the reported literature or as illustrated.


General Scheme 1: Synthesis of Thalidomide-based Degraders – Amides and Esters

wherein R₁₃, R₁₄, R₁₅, R₁₆, Z₂, W, p₁, q, and s are as defined herein above.

The general way of preparing representative compounds of the present application (*i.e.*,
 5 Compound of Formula (I) shown above) using intermediates **1a**, **1b**, **1c**, **1d**, **1e**, **1f**, and **1g** is outlined in **General Scheme 1**. Reaction of glutarimide (or δ -valerolactam) derivatives **1a** with phthalic anhydride derivatives **1b** in the presence of a base, *i.e.*, diisopropylethylamine (DIPEA), and in a solvent, *i.e.*, dimethylformamide (DMF), provided intermediates **1c**. Reaction of esters **1d** with **1c** provided intermediates **1e**. Deprotection of **1e** in the presence of TFA in a solvent, *i.e.*, dichloromethane (DCM) or methanol (MeOH), provided **1f**. Coupling of **1f** and Target Ligands **1g**, wherein “X” is NH(CH₃)), under standard peptide coupling conditions using a coupling reagent, *i.e.*, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and hydroxybenzotriazole, in a solvent, *i.e.*, DCM or DMF, provided bifunctional compound of Formula (I).
 10


Alternatively, glutarimide derivative **1a** may be replaced with the corresponding δ -lactam derivative, *e.g.*, δ -valerolactam, to provide bifunctional compounds including degrons of Formulae D1g and D1g’.
 15

Alternatively, targeting ligands **1g**, wherein “X” is OH, may be coupled to intermediates **1f** via known esterification conditions, *e.g.*, Fischer esterification conditions by treatment with acid, Yamaguchi esterification conditions via conversion of the acid to an appropriate anhydride,
 20 or Steglich esterification conditions by treatment with a coupling agent such as dicyclohexylcarbodiimide.

General Scheme 2: Synthesis of Thalidomide-based Degraders – Triazoles

wherein R_{13} , R_{14} , R_{15} , R_{16} , Z_2 , W , p_1 , q , and s are as defined herein above.

- 5 A general way of preparing representative compounds of the present application (*i.e.*, Compound of Formula (II) shown above) using intermediates **1a**, **1b**, **1c**, **1h**, **1i**, **1j**, and **1k** is outlined in **General Scheme 2**. Intermediates **1c** may be prepared according to General Scheme 1, and subsequently coupled to amines **1h** under the conditions provided in General Scheme 1 to provide intermediates **1i**. The aldehyde of intermediate **1i** may be converted to the terminal
- 10 alkyne of intermediate **1j** under typical Corey-Fuchs homologation conditions, *i.e.*, treatment with carbon tetrabromide in the presence of triphenylphosphine, followed by treatment of the resulting 1,1-dibromoolefin with *n*-butyllithium. Alternatively, amines **1h** may be protected with suitable protecting groups, subjected to Corey-Fuchs conditions, and further deprotected prior to coupling with **1c**. Alkyne **1j** may be coupled to Targeting Ligands **1k**, wherein X is N_3 , under
- 15 standard Click reaction conditions, *i.e.*, by treatment with a copper catalyst.


General Scheme 3: Synthesis of Thalidomide-based Degraders – Heterocycles (a)

wherein R_{13} , R_{14} , R_{15} , R_{16} , Z_2 , W , p_1 , q , and s are as defined herein above.

A general way of preparing representative compounds of the present application (*i.e.*, Compound of Formula (III) shown above) using intermediates **1a**, **1b**, **1c**, **1h**, **1i**, **1j**, and **1m** is outlined in **General Scheme 3**. Intermediates **1c** may be prepared according to General Scheme 1, and subsequently coupled to amines **1h** under the conditions provided in General Scheme 1 to provide intermediates **1i**. Olefination under standard Wittig conditions may afford the corresponding olefin (not shown) and subsequent treatment with bromine may provide dibromide **1j**. Targeting ligand **1m** may be prepared in a similar manner, *i.e.*, under Mitsunobu conditions with ethanolamine, ethylenediamine, or derivatives thereof, as shown in the examples below. Alternatively, ethanolamine or ethylenediamine moieties may be installed via reductive amination between Targeting Ligand-NH₂ and *O*-protected 2-hydroxyacetaldehyde or *N*-protected aminoacetaldehyde, respectively. Under conditions effective to encourage substitution, *e.g.*, in the presence of a base catalyst, reaction between Target Ligand **1m** and dibromide **1j** may afford compounds of Formula (III).

It should be understood that the steps in any of the schemes disclosed herein may be performed in a different order. For example, the Wittig olefination of **1i** may instead be performed on aldehyde **1h**.

General Scheme 4: Synthesis of Thalidomide-based Degraders – Heterocycles (b)





wherein R₁₃, R₁₄, R₁₅, R₁₆, Z₂, W, p₁, q, and s are as defined herein above.

A general way of preparing representative compounds of the present application (*i.e.*, Compound of Formula (IV) shown above) using intermediates **1a**, **1b**, **1c**, **1n**, **1o**, **1p**, and **1q** is outlined in **General Scheme 4**. Intermediates **1c** may be prepared according to General Scheme 1, and subsequently coupled to amines **1n** under the conditions provided in General Scheme 1 to provide intermediates **1o**. An example amine **1n** may be prepared by polymerizing ethylene oxide with *N*-protected ethanolamine, wherein W is O, followed by *N*-deprotection. The alcohol

of intermediates **1o** may be converted to a suitable leaving group, such as a tosylate (not shown). The resulting tosylate may be substituted with azide and the azide compound (not shown) may further be reduced under standard Staudinger conditions, *e.g.*, treatment with phosphine, to afford amine intermediates **1p**. Targeting Ligand **1q** may be prepared, for example, via two sequential reductive amination events between Targeting Ligand-NH₂ and an *O*-protected 2-hydroxyacetaldehyde, *i.e.*, two separate reductive amination reactions, each with different *O*-protecting groups that are cleavable under different conditions, *e.g.*, -OBn and -OtBu. *O*-deprotection, followed by conversion of the resulting alcohol(s) to a suitable leaving group, such as tosylate. The resulting tosylate may undergo substitution with amine **1p**, in the presence of an acid or base catalyst, to provide compounds of Formula (IV).

General Scheme 5





In General Scheme 5, compound (a) may be obtained commercially as a single stereoisomer, and as either saturated or unsaturated as indicated.

Step i) Compound (a) may be protected as ketal (b), for example, with a suitable diol or thiol in the presence of an acid, *e.g.*, ethylene glycol and tosylic acid. Ketal (b) may be subjected to Mitsunobu conditions (*e.g.*, a phosphine such as triphenylphosphine; an azodicarboxylate such as diethylazodicarboxylate; and a nucleophile such as an azide, *e.g.*, diphenyl phosphoryl azide) to form azide (c). Other nucleophiles may be readily envisioned.


Step ii) Azide (c) may undergo a Click reaction in the presence of a suitable alkyne, such as TMS-acetylene, and a copper catalyst. Azide (c) may also be used to prepare various amino-substituted intermediates. For example, saturated azide (c) may be hydrogenated under standard hydrogenation conditions, *e.g.*, H₂ and Pd/C. Unsaturated azide (c) may similarly be reduced under Staudinger conditions to provide amine (e), *i.e.*, by treatment with a phosphine such as trimethylphosphine. Amine (e) may undergo reductive amination and/or alkylation. For example, reductive amination conditions may include imine formation with a suitable aldehyde, *e.g.*, formaldehyde, or ketone, followed by treatment with a reducing agent such as sodium borohydride. For example, alkylation conditions may include treating amine (e), in the presence of a base, with a suitable alkylating agent such as an alkyl halide, *e.g.*, ethyl iodide, 1,4-dibromoethane, or 2-bromoethyl ether. Alternatively, amine (e) may undergo mono-protection prior to alkylation, for example, as the boc amine, by treatment with boc anhydride. Deprotection of a boc amine may be afforded by treatment with an acid, such as trifluoroacetic acid. For example, deprotection may be carried out on compound (i) or (j).

Step iii) The ketones of amine (f) or triazole (d) may be deprotected by treatment with a suitable acid such as tosylic acid and subsequently converted to the corresponding vinyl triflate (h). For example, triflate (h) may be provided by treatment of ketone (g) with a non-

nucleophilic base, such as KHMDS, and suitable electrophilic triflate source, such as *N*-phenyl-bis(trifluoromethanesulfonimide) or triflic anhydride.

Step iv) Triflate (**h**) may be coupled to a variety of heteraryl groups (“HET”). For example, triflate (**h**) may be contacted with a HET-boronic acid or HET-boronate ester in the presence of a suitable palladium catalyst, *i.e.*, Suzuki cross-coupling. Other cross-coupling reactions are readily envisioned, for example contacting triflate (**h**) with a HET-Sn(alkyl)₃ reagent in the presence of a palladium catalyst, *i.e.*, Stille cross-coupling. Compound (**i**) may further be reduced to afford compound (**j**), for example, by treatment with a diimide reducing agent, such as potassium azodicarboxylate.

10 General Scheme 6



In General Scheme 6, compound (**m**) may be obtained commercially as a single stereoisomer, and as either saturated or unsaturated as indicated by the figure.

Compound (**m**) may be subjected to cross-coupling conditions in order to install a suitable heteroaryl group (“HET”), and the resulting compound (**n**) may further be reduced. Each step may be carried out as described above in General Scheme 5.

Biological Assays

The biological activities of the compounds of the present application can be assessed through a variety of methods known in the art. For example, a kinase competitive binding assay may be used to determine the activity of the compounds of the present application to bind to CD8 and/or CD19. In the competitive binding assay, a reporting ligand capable of binding to CD8 and/or CD19, such as a fluoro- or radio-labeled compound, is incubated with CD8 and/or CD19 in the absence of a compound of the present application or with increasing concentrations of the compound. The changes in the signal produced by the reporting ligand when the compound is present relative when the compound is absent are recorded, which are calculated to provide the IC₅₀ of the compound.

Methods of the Application

In one aspect, the present application provides a method of modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, a cyclin-dependent kinase, such as CDK8 and/or CDK19). The method comprises administering to a subject in need thereof an effective amount
5 of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application.

In one aspect, the present application provides a method of modulating (*e.g.*, inhibiting or decreasing the amount of) CDK8 and/or CDK19. The method comprises administering to a subject in need thereof an effective amount of a bifunctional compound of the application or an
10 enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application.

In some embodiments, the inhibition or degradation of CDK8 and/or CDK19 activity is measured by IC₅₀. In some embodiments, the inhibition or degradation of CDK8 and/or CDK19 activity is measured by EC₅₀.

15 A bifunctional compound of the present application (*e.g.*, a compound of any of the formulae described herein, or selected from any compounds described herein) is capable of treating or preventing a disease or disorder in which CDK8 and/or CDK 19 plays a role or in which CDK8 and/or CDK19 is deregulated (*e.g.*, overexpressed).

In one aspect, the present application provides a method of treating or preventing a
20 disease responsive to modulation of CDK8 and/or CDK19. The method comprises administering to a subject in need thereof an effective amount of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application.

In one aspect, the present application provides a method of treating or preventing a
25 disease. The method comprises administering to a subject in need thereof an effective amount of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application. In one aspect, the disease is a kinase (*e.g.*, CDK8 and/or CDK19) mediated disorder. In one aspect, the disease is a proliferative disease (*e.g.*, a proliferative disease in which CDK8 and/or CDK19
30 plays a role).

In one aspect, the present application provides a method of treating or preventing cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or activated CDK19 or wherein the subject is identified as being in need of inhibition of CDK8 and/or CDK19 for the treatment or prevention of cancer. The method comprises administering to the
5 subject an effective amount of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application.

In one embodiment, the disease (*e.g.*, cancer) is mediated by CDK8 and/or CDK19 (*e.g.*, CDK8 and/or CDK19 plays a role in the initiation or development of the disease).

10 In one embodiment, the CDK8 activation is selected from mutation of CDK8, amplification of CDK8, overexpression of CDK8, and ligand mediated activation of CDK8.

In one embodiment, the CDK19 activation is selected from mutation of CDK19, amplification of CDK19, overexpression of CDK19, and ligand mediated activation of CDK19.

In one embodiment, the present application provides a method of treating or preventing
15 any of the diseases, disorders, and conditions described herein, wherein the subject is a human. In one embodiment, the application provides a method of treating. In one embodiment, the application provides a method of preventing.

As inhibitors or degraders of CDK8 and/or CDK19, the compounds and compositions of this application are particularly useful for treating or lessening the severity of a disease,
20 condition, or disorder where a protein kinase is implicated in the disease, condition, or disorder. In one embodiment, the present application provides a method for treating or lessening the severity of a disease, condition, or disorder where a protein kinase is implicated in the disease state. In one embodiment, the present application provides a method for treating or lessening the severity of a kinase disease, condition, or disorder where inhibition of enzymatic activity is
25 implicated in the treatment of the disease. In one embodiment, the present application provides a method for treating or lessening the severity of a disease, condition, or disorder with compounds that inhibit enzymatic activity or degrade the enzymes by binding to the protein kinase. In one embodiment, the present application provides a method for treating or lessening the severity of a
30 kinase disease, condition, or disorder by inhibiting enzymatic activity of the kinase or degrading the kinase with a protein kinase inhibitor or degrader.

In one embodiment, the disease or disorder is cancer or a proliferation disease.

In one embodiment, the disease or disorder is lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, pancreas cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemias, lymphomas, myelomas, or solid tumors.

In one embodiment, the disease or disorder is inflammation, arthritis, rheumatoid arthritis, spondylarthropathies, gouty arthritis, osteoarthritis, juvenile arthritis, and other arthritic conditions, systemic lupus erthematosus (SLE), skin-related conditions, psoriasis, eczema, burns, dermatitis, neuroinflammation, allergy, pain, neuropathic pain, fever, pulmonary disorders, lung inflammation, adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, silicosis, chronic pulmonary inflammatory disease, and chronic obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction (including post-myocardial infarction indications), thrombosis, congestive heart failure, cardiac reperfusion injury, as well as complications associated with hypertension and/or heart failure such as vascular organ damage, restenosis, cardiomyopathy, stroke including ischemic and hemorrhagic stroke, reperfusion injury, renal reperfusion injury, ischemia including stroke and brain ischemia, and ischemia resulting from cardiac/coronary bypass, neurodegenerative disorders, liver disease and nephritis, gastrointestinal conditions, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, ulcerative diseases, gastric ulcers, viral and bacterial infections, sepsis, septic shock, gram negative sepsis, malaria, meningitis, HIV infection, opportunistic infections, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), pneumonia, herpes virus, myalgias due to infection, influenza, autoimmune disease, graft vs. host reaction and allograft rejections, treatment of bone resorption diseases, osteoporosis, multiple sclerosis, cancer, leukemia, lymphoma, colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma), basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, squamous cell and/or basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that affect epithelial cells throughout the body, chronic myelogenous leukemia (CML), acute myeloid leukemia (AML)

and acute promyelocytic leukemia (APL), angiogenesis including neoplasia, metastasis, central nervous system disorders, central nervous system disorders having an inflammatory or apoptotic component, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, peripheral neuropathy, or B-Cell Lymphoma.

5 In one embodiment, the disease or disorder is inflammation, arthritis, rheumatoid arthritis, spondylarthropathies, gouty arthritis, osteoarthritis, juvenile arthritis, and other arthritic conditions, systemic lupus erthematosus (SLE), skin-related conditions, psoriasis, eczema, dermatitis, pain, pulmonary disorders, lung inflammation, adult respiratory distress syndrome, pulmonary sarcoisosis, asthma, chronic pulmonary inflammatory disease, and chronic
10 obstructive pulmonary disease (COPD), cardiovascular disease, arteriosclerosis, myocardial infarction (including post-myocardial infarction indications), congestive heart failure, cardiac reperfusion injury, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, leukemia, or lymphoma.

In one embodiment, the disease or disorder is selected from autoimmune diseases,
15 inflammatory diseases, proliferative and hyperproliferative diseases, immunologically-mediated diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cardiovascular diseases, hormone related diseases, allergies, asthma, and Alzheimer's disease. In one embodiment, the disease or disorder is selected from a proliferative disorder and a neurodegenerative disorder.

20 In one embodiment, the disease or disorder is characterized by excessive or abnormal cell proliferation. Such diseases include, but are not limited to, a proliferative or hyperproliferative disease, and a neurodegenerative disease. Examples of proliferative and hyperproliferative diseases include, without limitation, cancer.

The term "cancer" includes, but is not limited to, the following cancers: breast; ovary;
25 cervix; prostate; testis, genitourinary tract; esophagus; larynx, glioblastoma; neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma; bone; colon; colorectal; adenoma; pancreas, adenocarcinoma; thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladder carcinoma; liver carcinoma and biliary passages; kidney carcinoma;
30 myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine; colonrectum, large intestine, rectum, brain and

central nervous system; chronic myeloid leukemia (CML), and leukemia. The term "cancer" includes, but is not limited to, the following cancers: myeloma, lymphoma, or a cancer selected from gastric, renal, or and the following cancers: head and neck, oropharangeal, non-small cell lung cancer (NSCLC), endometrial, hepatocarcinoma, Non-Hodgkins lymphoma, and pulmonary.

The term "cancer" also refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphomas and the like. For example, cancers include, but are not limited to, mesothelioma, leukemias and lymphomas such as cutaneous T-cell lymphomas (CTCL), noncutaneous peripheral T-cell lymphomas, lymphomas associated with human T-cell lymphotropic virus (HTLV) such as adult T-cell leukemia/lymphoma (ATLL), B-cell lymphoma, acute nonlymphocytic leukemias, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, lymphomas, and multiple myeloma, non-Hodgkin lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), Hodgkin's lymphoma, Burkitt lymphoma, adult T-cell leukemia lymphoma, acute-myeloid leukemia (AML), chronic myeloid leukemia (CML), or hepatocellular carcinoma. Further examples include myelodysplastic syndrome, childhood solid tumors such as brain tumors, neuroblastoma, retinoblastoma, Wilms' tumor, bone tumors, and soft-tissue sarcomas, common solid tumors of adults such as head and neck cancers (*e.g.*, oral, laryngeal, nasopharyngeal and esophageal), genitourinary cancers (*e.g.*, prostate, bladder, renal, uterine, ovarian, testicular), lung cancer (*e.g.*, small-cell and non-small cell), breast cancer, pancreatic cancer, melanoma and other skin cancers, stomach cancer, brain tumors, tumors related to Gorlin's syndrome (*e.g.*, medulloblastoma, meningioma, *etc.*), and liver cancer. Additional exemplary forms of cancer which may be treated by the subject compounds include, but are not limited to, cancer of skeletal or smooth muscle, stomach cancer, cancer of the small intestine, rectum carcinoma, cancer of the salivary gland, endometrial cancer, adrenal cancer, anal cancer, rectal cancer, parathyroid cancer, and pituitary cancer.

Cancer may also include colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, or melanoma. Further, cancers include, but are not limited to, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, thyroid cancer (medullary and papillary thyroid carcinoma), renal carcinoma, kidney parenchyma carcinoma, cervix carcinoma,

uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, gall bladder carcinoma, bronchial carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, 5 seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.

Cancer may also include colorectal, thyroid, breast, and lung cancer; and myeloproliferative disorders, such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, chronic myelogenous leukemia, chronic myelomonocytic leukemia, 10 hypereosinophilic syndrome, juvenile myelomonocytic leukemia, and systemic mast cell disease. In one embodiment, the compounds of this application are useful for treating hematopoietic disorders, in particular, acute-myelogenous leukemia (AML), chronic-myelogenous leukemia (CML), acute-promyelocytic leukemia, and acute lymphocytic leukemia (ALL).

Examples of neurodegenerative diseases include, without limitation, 15 Adrenoleukodystrophy (ALD), Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's Disease), Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, Familial fatal insomnia, Frontotemporal lobar degeneration, Huntington's disease, HIV- 20 associated dementia, Kennedy's disease, Krabbe's disease, Lewy body dementia, Neuroborreliosis, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple System Atrophy, Multiple sclerosis, Narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Progressive Supranuclear Palsy, Refsum's disease, Sandhoff disease, Schilder's disease, Subacute combined 25 degeneration of spinal cord secondary to Pernicious Anaemia, Spielmeyer-Vogt-Sjogren-Batten disease (also known as Batten disease), Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, and Toxic encephalopathy.

In one aspect, the present application also provides a method of treating or preventing 30 cell proliferative disorders such as hyperplasias, dysplasias, or pre-cancerous lesions. Dysplasia is the earliest form of pre-cancerous lesion recognizable in a biopsy by a pathologist. The

compounds of the present application may be administered for the purpose of preventing hyperplasias, dysplasias, or pre-cancerous lesions from continuing to expand or from becoming cancerous. Examples of pre-cancerous lesions may occur in skin, esophageal tissue, breast, and cervical intra-epithelial tissue.

5 As inhibitors or degraders of CDK8 and/or CDK19, the compounds and compositions of this application are also useful in assessing, studying, or testing biological samples. One aspect of the application relates to inhibiting protein kinase activity or degrading protein kinase in a biological sample, comprising contacting the biological sample with a compound or a composition of the application.

10 The term "biological sample", as used herein, means an *in vitro* or an *ex vivo* sample, including, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. Inhibition of protein kinase activity or degradation of protein kinase in a biological sample is useful for a variety of purposes that are known to one of skill in the art.

15 Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, and biological specimen storage.

Another aspect of this application relates to the study of CDK8 and/or CDK19 in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such protein kinases; and the comparative evaluation of new protein kinase
20 inhibitors. Examples of such uses include, but are not limited to, biological assays such as enzyme assays and cell-based assays.

The activity of the compounds and compositions of the present application as CDK8 and/or CDK19 inhibitors or degraders may be assayed *in vitro*, *in vivo*, or in a cell line. *In vitro* assays include assays that determine inhibition of either the kinase activity or ATPase activity or
25 degradation of the activated kinase. Alternate *in vitro* assays quantitate the ability of the inhibitor or degrader to bind to the protein kinase and may be measured either by radio labelling the inhibitor or degrader prior to binding, isolating the inhibitor/kinase or degrader/kinase complex and determining the amount of radio label bound, or by running a competition experiment where new inhibitors or degraders are incubated with the kinase bound to known
30 radioligands. Detailed conditions for assaying a compound utilized in this application as an inhibitor or degrader of various kinases are set forth in the Examples below.

In accordance with the foregoing, the present application provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application. For any of the above uses, the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.

Compounds and compositions of the application can be administered in therapeutically effective amounts in a combinational therapy with one or more therapeutic agents (pharmaceutical combinations) or modalities, *e.g.*, an anti-proliferative, anti-cancer, immunomodulatory or anti-inflammatory agent. Where the compounds of the application are administered in conjunction with other therapies, dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth. Compounds and compositions of the application can be administered in therapeutically effective amounts in a combinational therapy with one or more therapeutic agents (pharmaceutical combinations) or modalities, *e.g.*, anti-proliferative, anti-cancer, immunomodulatory or anti-inflammatory agent, and/or non-drug therapies, *etc.* For example, synergistic effects can occur with anti-proliferative, anti-cancer, immunomodulatory or anti-inflammatory substances. Where the compounds of the application are administered in conjunction with other therapies, dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.

Combination therapy includes the administration of the subject compounds in further combination with one or more other biologically active ingredients (such as, but not limited to, a second CDK8 inhibitor, a second CDK19 inhibitor, a second and different antineoplastic agent, a second cyclin-dependent kinase inhibitor (*i.e.*, CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK11, CDK12, CDK13, CDK14, *etc.*) and non-drug therapies (such as, but not limited to, surgery or radiation treatment). For instance, the compounds of the application can be used in combination with other pharmaceutically active compounds, preferably compounds that are able to enhance the effect of the compounds of the application. The compounds of the application can be administered simultaneously (as a single preparation or separate preparation) or

sequentially to the other drug therapy or treatment modality. In general, a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy.

In another aspect of the application, the compounds may be administered in combination with one or more separate pharmaceutical agents, *e.g.*, a chemotherapeutic agent, an immunotherapeutic agent, or an adjunctive therapeutic agent.

Another aspect of the present application relates to a kit comprising a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application.

Another aspect of the present application relates to a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, a cyclin-dependent kinase, such as CDK8 and/or CDK19), for treating or preventing a disease (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role), or for treating or preventing cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or activated CDK19 or wherein the subject is identified as being in need of inhibition of CDK8 and/or CDK19 for the treatment or prevention of cancer.

Another aspect of the present application relates to use of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, in the manufacture of a medicament for modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, a cyclin-dependent kinase, such as CDK8 and/or CDK19), for treating or preventing a disease (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role), or for treating or preventing cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or activated CDK19 or wherein the subject is identified as being in need of inhibition of CDK8 and/or CDK19 for the treatment or prevention of cancer.

Another aspect of the present application relates to a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, for use in modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, a cyclin-dependent kinase, such as CDK8 and/or CDK19), in treating or preventing a disease (*e.g.*, a disease in which CDK8 and/or

CDK19 plays a role), or in treating or preventing cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or activated CDK19 or wherein the subject is identified as being in need of inhibition of CDK8 and/or CDK19 for the treatment or prevention of cancer.

Another aspect of the present application relates to use of a bifunctional compound of the application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the application, in modulating (*e.g.*, inhibiting or decreasing the amount of) a kinase (*e.g.*, a cyclin-dependent kinase, such as CDK8 and/or CDK19), in treating or preventing a disease (*e.g.*, a disease in which CDK8 and/or CDK19 plays a role), or in treating or preventing cancer in a subject, wherein the cell of the cancer comprises an activated CDK8 and/or activated CDK19 or wherein the subject is identified as being in need of inhibition of CDK8 and/or CDK19 for the treatment or prevention of cancer.

Pharmaceutical Compositions

In another aspect, the application provides a pharmaceutical composition comprising a therapeutically effective amount of a bifunctional compound of the present application or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Compounds of the application can be administered as pharmaceutical compositions by any conventional route, in particular enterally, *e.g.*, orally, *e.g.*, in the form of tablets or capsules, or parenterally, *e.g.*, in the form of injectable solutions or suspensions, or topically, *e.g.*, in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.

Pharmaceutical compositions comprising a bifunctional compound of the present application in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets or gelatin capsules comprising the active ingredient together with a) diluents, *e.g.*, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, *e.g.*, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, *e.g.*, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, *e.g.*, starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions can be aqueous isotonic solutions or

suspensions, and suppositories can be prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Suitable formulations for transdermal applications include an effective amount of a bifunctional compound of the present application with a carrier. A carrier can include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Matrix transdermal formulations may also be used. Suitable formulations for topical application, *e.g.*, to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

The pharmaceutical compositions of the present application comprise a therapeutically effective amount of a bifunctional compound of the present application formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylenepolyoxy propylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar;

buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water, isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

The pharmaceutical compositions of this application can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable preparations, for example, sterile injectable aqueous, or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of

absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

5 Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this application with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

10 Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, *e.g.*, tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

20 Dosage forms for topical or transdermal administration of a compound of this application include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this application.

30 The ointments, pastes, creams and gels may contain, in addition to an active compound of this application, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this application, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

5 Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

10

EXAMPLES

Analytical Methods, Materials, and Instrumentation

All reactions were monitored by thin layer chromatography (TLC) with 0.25 mm E. Merck pre-coated silica gel plates (60 F₂₅₄), Waters LCMS system (Waters 2489 UV/Visible
15 Detector, Waters 3100 Mass, Waters 515 HPLC pump, Waters 2545 Binary Gradient Module, Waters Reagent Manager, Waters 2767 Sample Manager) using SunFire™ C18 column (4.6 x 50 mm, 5 μm particle size): solvent gradient = 100% A at 0 min, 1% A at 5 min; solvent A = 0.035% TFA in Water; solvent B = 0.035% TFA in MeOH; flow rate : 2.5 mL/min, and/or Waters Acquity UPLC/MS system (Waters PDA eλ Detector, QDa Detector, Sample manager –
20 FL, Binary Solvent Manager) using Acquity UPLC® BEH C18 column (2.1 x 50 mm, 1.7 μm particle size): solvent gradient = 90% A at 0 min, 1% A at 1.8 min; solvent A = 0.1% formic acid in Water; solvent B = 0.1% formic acid in Acetonitrile; flow rate : 0.6 mL/min. Reaction products were purified by flash column chromatography using CombiFlash®Rf with Teledyne Isco RediSep®Rf High Performance Gold or Silicycle SiliaSep™ High Performance columns (4
25 g, 12 g, 24 g, 40 g, or 80 g), Waters HPLC system using SunFire™ Prep C18 column (19 x 100 mm, 5 μm particle size): solvent gradient = 80% A at 0 min, 5% A at 25 min; solvent A = 0.035% TFA in Water; solvent B = 0.035% TFA in MeOH; flow rate : 25 mL/min (Method A), and Waters Acquity UPLC/MS system (Waters PDA eλ Detector, QDa Detector, Sample manager – FL, Binary Solvent Manager) using Acquity UPLC® BEH C18 column (2.1 x 50
30 mm, 1.7 μm particle size): solvent gradient = 80% A at 0 min, 5% A at 2 min; solvent A = 0.1% formic acid in Water; solvent B = 0.1% formic acid in Acetonitrile; flow rate : 0.6 mL/min


(method B). The purity of all compounds was over 95% and was analyzed with Waters LCMS system. ^1H NMR was obtained using a 500 MHz Bruker Avance III. Chemical shifts are reported relative to dimethyl sulfoxide ($\delta = 2.50$) or chloroform ($\delta = 7.26$) for ^1H NMR. Data are reported as (*br* = broad, *s* = singlet, *d* = doublet, *t* = triplet, *q* = quartet, *m* = multiplet).

5 Abbreviations used in the following examples and elsewhere herein are:

	AcOH	acetic acid
	atm	atmosphere
	Boc ₂ O	di-tert-butyl dicarbonate
	BuLi	<i>n</i> -butyllithium
10	br	broad
	CBr ₄	carbon tetrabromide
	CDCl ₃	deuterated chloroform
	DCM	dichloromethane
	DIEA	N,N-diisopropylethylamine
15	DMAP	4-dimethylaminopyridine
	DMA	N,N-dimethylacetamide
	DMF	N,N-dimethylformamide
	DMSO	dimethyl sulfoxide
	DMSO- <i>d</i> ₆	deuterated dimethyl sulfoxide
20	EDCI	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
	ESI	electrospray ionization
	EtOAc	ethyl acetate
	HCl	hydrochloric acid
	h	hour(s)
25	HATU	bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluoro-phosphate
	HPLC	high-performance liquid chromatography
	Hz	hertz
	KHMDS	potassium hexamethylsilazide
30	LCMS	liquid chromatography--mass spectrometry
	m	multiplet
	mL	milliliter
	MeCN	acetonitrile
	MeOH	methanol
35	g	milligram
	mmol	millimole
	MgSO ₄	magnesium sulfate

	MHz	megahertz
	min	minutes
	MS	mass spectrometry
	Na ₂ CO ₃	sodium carbonate
5	NaHCO ₃	sodium bicarbonate
	NMR	nuclear magnetic resonance
	Tf	triflate
	Pd ₂ (dba) ₃	tris(dibenzylideneacetone)dipalladium(0)
	Pd(PPh ₃) ₂ Cl ₂	bis(triphenylphosphine)palladium(II) dichloride
10	PhN(SO ₂ CF ₃) ₂	N-phenyl-bis(trifluoromethanesulfonamide)
	PMes	trimethylphosphine
	PPh ₃	triphenylphosphine
	ppm	parts per million
	PTSA	para-toluene sulfonic acid
15	TBAF	tetra-n-butylammonium fluoride
	t-BuOH	tert-butanol
	TFA	trifluoroacetic acid
	TMS	trimethylsilane
	THF	tetrahydrofuran
20	TLC	thin layer chromatography
	μL	microliter
	Xphos	2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

Example 1: (3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-17-(isoquinolin-7-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (1)



To a solution of (3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-17-iodo-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (50 mg, 0.13 mmol) in 1,4-dioxane (5 mL) and Na₂CO₃ 2M aq. (0.32 mL, 0.63 mmol) was added isoquinolin-7-ylboronic acid (25 mg, 0.14 mmol). The solution was thoroughly degassed and then Pd(PPh₃)₂Cl₂ (5 mg, 0.006 mmol) was added and the mixture was heated to 90 °C for 1 hour.

30

The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL), dried over MgSO₄, and condensed to give a brown oil that was purified by reverse phase chromatography using a gradient of 1-90% MeCN in H₂O to give the title compound (**1**) as a beige solid (40 mg, 80% yield). ¹H NMR (500 MHz, DMSO-d₆): δ 9.66 (s, 1H), 8.55 (d, *J* = 5Hz, 1H), 8.35 (s, 1H), 8.20 (d, *J* = 6Hz, 1H), 8.13 (s, 2H), 6.39 (s, 1H), 5.33 (s, 1H), 3.28 (m, 1H), 3.17 (s, 1H), 2.38-1.99 (m, 6H), 1.81-1.52 (m, 8H), 1.45-1.33 (m, 3H), 1.15 (s, 3H), 1.03 (s, 3H). MS m/z 400.39 [M+H]⁺.

Compounds **2-7** in Table 1 above were prepared by this procedure from appropriate starting materials and appropriate boronic ester/acid.

10 Compound **2**:

76% yield. ¹H NMR (500 MHz, DMSO-d₆): δ 9.65 (s, 1H), 8.56 (d, *J* = 5Hz, 1H), 8.32 (s, 1H), 8.17 (d, *J* = 6Hz, 1H), 8.12 (s, 2H), 6.37 (s, 1H), 3.38 (m, 1H), 3.17 (s, 1H), 2.41-2.22 (m, 3H), 1.75-1.14 (m, 17H), 1.11 (s, 3H), 0.84 (s, 3H). LCMS m/z 401.74 [M+H]⁺.

Compound **3**:

15 68% yield. ¹H NMR (500 MHz, DMSO-d₆): δ 9.86 (s, 1H), 9.80 (s, 1H), 8.28 (s, 1H), 8.24 (d, *J* = 6Hz, 2H), 6.51 (s, 1H), 5.34 (s, 1H), 3.26 (m, 1H), 3.17 (s, 1H), 2.41-1.87 (m, 6H), 1.83-1.54 (m, 8H), 1.41-1.30 (m, 3H), 1.11 (s, 3H), 1.01 (s, 3H). LCMS m/z 400.86 [M+H]⁺.

Compound **4**:

20 60% yield. ¹H NMR (500 MHz, DMSO-d₆): δ 9.38 (s, 1H), 8.06 (br, 2H), 7.89 (s, 1H), 7.80 (d, *J* = 6Hz, 1H), 7.54 (d, *J* = 6Hz, 1H), 6.34 (s, 1H), 5.32 (s, 1H), 3.29 (m, 1H), 3.17 (s, 1H), 1.83-1.21 (m, 17H), 0.93 (s, 3H), 0.44 (s, 3H). LCMS m/z 416.37 [M+H]⁺.

Compound **5**:

25 54% yield. ¹H NMR (500 MHz, DMSO-d₆): δ 12.96 (s, 1H), 7.94 (s, 1H), 7.48 (s, 1H), 7.40 (d, *J* = 6Hz, 1H), 7.19 (d, *J* = 6Hz, 1H), 6.39 (s, 1H), 5.30 (s, 1H), 5.12 (s, 1H), 4.63 (s, 1H), 3.27 (m, 1H), 2.22-1.20 (m, 18H), 0.93 (s, 3H), 0.43 (s, 3H). LCMS m/z 403.61 [M+H]⁺.

Compound **6**:

58% yield. ¹H NMR (500 MHz, DMSO-d₆): δ 12.91 (s, 1H), 7.98 (s, 2H), 7.58 (s, 1H), 7.43 (d, *J* = 6Hz, 1H), 7.21 (d, *J* = 6Hz, 1H), 6.38 (s, 1H), 5.30 (s, 1H), 4.63 (s, 1H), 3.27 (m, 1H), 2.22-1.20 (m, 18H), 0.93 (s, 3H), 0.43 (s, 3H). LCMS m/z 389.48 [M+H]⁺.


30 Compound **7**:

53% yield. $^1\text{H NMR}$ (500 MHz, DMSO- d_6): δ 12.91 (s, 1H), 7.97 (s, 1H), 7.46 (s, 1H), 7.31 (d, $J = 6\text{Hz}$, 1H), 7.18 (d, $J = 6\text{Hz}$, 1H), 6.39 (s, 1H), 5.30 (s, 1H), 4.63 (s, 1H), 3.27 (m, 1H), 2.22-1.20 (m, 19H), 0.93 (s, 3H), 0.43 (s, 3H). MS m/z 389.48 $[\text{M}+\text{H}]^+$.

Compound **48**:

64% yield. $^1\text{H NMR}$ (500 MHz, DMSO- d_6): δ 9.47 (s, 1H), 8.44 (s, 1H), 8.20 (s, 2H), 8.11 (d, $J = 6\text{Hz}$, 1H), 7.95 (d, $J = 6\text{Hz}$, 1H), 6.40 (s, 1H), 5.30 (s, 1H), 3.29 (m, 1H), 2.97 (t, $J = 10\text{Hz}$, 1H), 2.30-1.96 (m, 5H), 1.85-1.26 (m, 12H), 0.91 (s, 3H), 0.43 (s, 3H). LCMS m/z 400.56 $[\text{M}+\text{H}]^+$.

Example 2: (3*S*,8*S*,9*S*,10*R*,13*S*,14*S*,17*S*)-17-(isoquinolin-7-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (8a**)**



To a solution of (3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-17-(isoquinolin-7-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol (**1**) (10 mg, 0.025 mmol) in DMSO/THF (1:1) (3 mL) was added potassium diazene-1,2-dicarboxylate (109 mg, 0.50 mmol) and AcOH (64 μL , 1 mmol) in 3 portions over 2 hours. The mixture was stirred at rt overnight. An additional 109 mg of diazene-1,2-dicarboxylate and 64 μL of AcOH was added and the mixture stirred 2 h. The mixture was quenched with sat. aq. NaHCO_3 and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with H_2O , brine, dried over MgSO_4 , and condensed to give a yellow oil that was purified by reverse phase HPLC using a gradient of 1-80% MeCN in H_2O to give the title compound (**8a**) as a brown oil (6 mg, 60 % yield). $^1\text{H NMR}$ (500 MHz, DMSO- d_6): δ 9.66 (s, 1H), 8.57 (s, 1H), 8.29 (s, 2H), 8.16 (d, $J = 6\text{Hz}$, 1H), 7.99 (d, $J = 6\text{Hz}$, 1H), 5.32 (s, 1H), 3.28 (m, 1H), 2.98 (t, $J = 10\text{Hz}$, 1H), 2.35-1.98 (m, 5H), 1.87-1.29 (m, 12H), 0.93 (s, 3H), 0.46 (s, 3H). MS m/z 402.39 $[\text{M}+\text{H}]^+$.

Compounds **8b** and **9-14** in Table 1 above were prepared by this preceding procedure from Compounds **2-7** and **1**, respectively.

Compound **8b**:

71% yield. ^1H NMR (500 MHz, DMSO- d_6) δ 9.68 (s, 1H), 8.54 (d, $J = 5\text{Hz}$, 1H), 8.37 (d, $J = 6\text{Hz}$, 1H), 8.31 (s, 1H), 8.19 (d, $J = 6\text{Hz}$, 1H), 8.04 (d, $J = 6\text{Hz}$, 1H), 3.36 (m, 1H), 3.17 (s, 1H), 2.97 (t, $J = 10\text{Hz}$, 1H), 2.41-2.22 (m, 3H), 1.78-1.12 (m, 17H), 0.72 (s, 3H), 0.41 (s, 3H). MS m/z 404.76 $[\text{M}+\text{H}]^+$.

5 Compound 9:

64% yield. ^1H NMR (500 MHz, DMSO- d_6) δ 9.86 (s, 1H), 9.80 (s, 1H), 8.28 (s, 1H), 8.24 (d, $J = 6\text{Hz}$, 2H), 5.31 (s, 1H), 4.87 (s, 1H), 3.26 (m, 1H), 3.17 (s, 1H), 2.41-1.87 (m, 6H), 1.83-1.54 (m, 10H), 1.41-1.30 (m, 3H), 1.09 (s, 3H), 0.98 (s, 3H). MS m/z 403.38 $[\text{M}+\text{H}]^+$.

Compound 10:

10 52% yield. ^1H NMR (500 MHz, DMSO- d_6) δ 9.36 (s, 1H), 8.14 (br, 2H), 7.91 (s, 1H), 7.86 (d, $J = 6\text{Hz}$, 1H), 7.57 (d, $J = 6\text{Hz}$, 1H), 5.33 (s, 1H), 4.72 (s, 1H), 3.29 (m, 1H), 3.17 (s, 1H),), 2.97 (t, $J = 10\text{Hz}$, 1H), 1.85-1.20 (m, 18H), 0.72 (s, 3H), 0.41 (s, 3H). MS m/z 417.96 $[\text{M}+\text{H}]^+$.

Compound 11:

15 48% yield. ^1H NMR (500 MHz, DMSO- d_6): δ 12.96 (s, 1H), 7.94 (s, 1H), 7.48 (s, 1H), 7.40 (d, $J = 6\text{Hz}$, 1H), 7.19 (d, $J = 6\text{Hz}$, 1H), 5.32 (s, 1H), 4.66 (s, 1H), 3.27 (m, 1H), 2.22-1.20 (m, 20H), 0.93 (s, 3H), 0.43 (s, 3H). MS m/z : 405.83 $[\text{M}+\text{H}]^+$.

Compound 12:

20 50% yield. ^1H NMR (500 MHz, DMSO- d_6): δ 12.91 (s, 1H), 7.98 (s, 1H), 7.58 (s, 1H), 7.43 (d, $J = 6\text{Hz}$, 1H), 7.21 (d, $J = 6\text{Hz}$, 1H), 5.31 (s, 1H), 4.67 (s, 1H), 3.27 (m, 1H), 2.22-1.20 (m, 20H), 0.92 (s, 3H), 0.44 (s, 3H). MS m/z : 391.28 $[\text{M}+\text{H}]^+$.

Compound 13:

25 53% yield. ^1H NMR (500 MHz, DMSO- d_6): δ 12.91 (s, 1H), 7.97 (s, 1H), 7.46 (s, 1H), 7.31 (d, $J = 6\text{Hz}$, 1H), 7.18 (d, $J = 6\text{Hz}$, 1H), 5.32 (s, 1H), 4.63 (s, 1H), 3.27 (m, 1H), 2.22-1.20 (m, 20H), 0.91 (s, 3H), 0.46 (s, 3H). MS m/z : 391.34 $[\text{M}+\text{H}]^+$.

Compound 14:

68% yield. ^1H NMR (500 MHz, DMSO- d_6): δ 9.36 (s, 1H), 8.14 (br, 2H), 7.91 (s, 1H), 7.86 (d, $J = 6\text{Hz}$, 1H), 7.57 (d, $J = 6\text{Hz}$, 1H), 5.33 (s, 1H), 3.29 (m, 1H), 3.17 (s, 1H),), 2.98 (t, $J = 10\text{Hz}$, 1H), 1.85-1.20 (m, 19H), 0.72 (s, 3H), 0.41 (s, 3H). MS m/z : 402.83 $[\text{M}+\text{H}]^+$.


Example 3: (3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-17-(isoquinolin-7-yl)-*N,N*,10,13-tetramethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-amine (22r)

Compound **22r** was prepared according to literature procedure. Czakó, *J. Am. Chem. Soc.* **2009**, *131*, 9014-9019.


To a solution of (3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-3-(dimethylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl trifluoromethanesulfonate (100 mg, 0.22 mmol) in 1,4-dioxane (5 mL) and 2M aq. Na₂CO₃ (0.55 mL, 1.1 mmol) was added isoquinolin-7-yl boronic acid (46 mg, 0.27 mmol). The mixture was thoroughly degassed and Pd(PPh₃)₂Cl₂ (8 mg, 0.011 mmol) was added. The mixture was stirred at 90 °C for 1 hour. The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with H₂O, brine, dried over MgSO₄, and condensed to give a yellow oil that was purified by reverse phase HPLC using a gradient of 1-70% MeCN in H₂O to give the title compound as a brown oil (38 mg, 40 % yield). MS m/z 429.39 [M+H]⁺.

Example 4: (3*S*,8*R*,9*S*,10*S*,13*S*,14*S*,17*S*)-(isoquinolin-7-yl)-*N,N*,10,13-tetramethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-amine (23)

Scheme 3.



20



Compound 22r was prepared according to literature procedure. Czakó B., *et al.*, *J. Am. Chem. Soc.* **2009**, *131*, 9014-9019. Compound 23 was prepared from compound 22r according to the reductive diimide procedure described above in the preparation of compound 8a. MS m/z 431.31 $[\text{M}+\text{H}]^+$.


Compounds 24 and 25 in Table I above were prepared in a similar manner as Compounds 22r and 23, respectively.


Compound 24: LCMS m/z 429.47 $[\text{M}+\text{H}]^+$.

10 Compound 25: LCMS m/z 431.82 $[\text{M}+\text{H}]^+$.

Example 5: (3S,8R,9S,10R,13S,14S)-17-(isoquinolin-7-yl)-N,N,10,13-tetramethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-amine (33)

15 **Scheme 4.**






Step 1: synthesis of intermediates 26-28

5 Intermediates 26-28 were prepared in a similar manner according to literature procedure, beginning with *cis*-dehydroepiandrosterone, as shown in Scheme 4. Czakó, B., *et al. J. Am. Chem. Soc.* **2009**, *131*, 9014-9019. Intermediate 29a was prepared as shown in Scheme 3.

Step 2: synthesis of intermediate 29a

Scheme 5.



10

(3*S*,8*R*,9*S*,10*R*,13*S*,14*S*)-3-azido-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolane] (**28**) (2 g, 5.59 mmol) was dissolved in anhydrous THF (50 mL). H₂O (503 μL, 28 mmol) was added after PMe₃ (1.15 mL, 11.2 mmol) was added. The mixture was stirred for 6 h. The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with H₂O,

15

brine, dried over MgSO₄, and condensed to give a yellow oil that was purified by flash chromatography using a gradient of 1-10% MeOH in DCM to give intermediate **29a** as a white solid (1.58 g, 85% yield). ¹H NMR (500 MHz, CDCl₃): δ 5.39 (s, 1H), 3.97-3.86 (m, 4H), 3.47 (br, 2H), 2.81 (m, 4H), 2.28 (m, 1H), 2.05-1.98 (m, 2H), 1.92-1.78 (m, 3H), 1.74- 1.67 (m, 1H), 1.64-1.38 (m, 9H), 1.32-1.24 (m, 1H), 1.15-1.07 (m, 1H), 1.03 (s, 3H), 0.88 (s, 3H). MS m/z 332.47 [M+H]⁺.

Steps 3 and 4: synthesis of compounds 32 and 33

Compounds **32** and **33** were prepared from intermediate **29a**, as shown above in Scheme 4.

10 Compound **32**:

¹H NMR (500 MHz, DMSO-d₆): δ 9.65 (s, 1H), 8.57 (d, J = 6Hz, 1H), 8.33 (s, 1H), 8.17 (d, J = 6Hz, 1H), 8.12 (s, 2H), 6.39 (s, 1H), 5.49 (s, 1H), 3.17 (s, 1H), 3.04 (m, 4H), 2.78 (s, 6H), 2.45-2.26 (m, 5H), 1.98-1.88 (m, 3H), 1.81-1.55 (m, 6H), 1.49-1.41 (m, 1H), 1.17 (s, 3H), 1.06 (s, 3H). MS m/z: 427.29 [M+H]⁺.

15 Compound **33**:


¹H NMR (500 MHz, DMSO-d₆): δ 9.72 (s, 1H), 8.61 (d, J = 6Hz, 1H), 8.35 (d, J = 6Hz, 1H), 8.33 (s, 1H), 8.20 (d, J = 6Hz, 1H), 8.03 (d, J = 6Hz, 1H), 5.47 (s, 1H), 3.44 (m, 1H), 3.0 (t, J = 10Hz, 1H), 2.77 (s, 6H), 2.44-2.27 (m, 5H), 1.68-1.28 (m, 12H), 1.16-1.00 (m, 4H), 0.96 (s, 3H), 0.47 (s, 3H). MS m/z: 429.58 [M+H]⁺.

20 **Example 6: 4-((3S,5S,8R,10S,13S,14S,17S)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)morpholine (34)**

Compound **34** was prepared in an analogous manner as demonstrated in Czakó, B., *et al. J. Am. Chem. Soc.* **2009**, *131*, 9014-9019, *i.e.*, the unsaturated equivalent of intermediate **29a** was treated with 2-bromoethyl ether and NaHCO₃ in toluene to the corresponding morpholine compound; the ketal was removed with *para*-toluene sulfonic acid (PTSA) in acetone and the resulting ketone was converted to the vinyl triflate with potassium hexamethyldisilazide (KHMDS) and PhN(SO₂CF₃)₂ in THF. The vinyl triflate was subsequently coupled with isoquinoline boronic acid under the Suzuki conditions described throughout.

30 **Example 7: 7-((3S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-(1H-1,2,3-triazol-1-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)isoquinoline (39)**

Scheme 6.



Step 1: synthesis of intermediate 35

5 To a solution of (3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-3-azido-10,13-dimethylhexadecahydrospiro-[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolane] (500 mg, 1.39 mmol) in *t*-BuOH (10 mL) and H₂O (3 mL) was added CuSO₄·5H₂O (18 mg, 0.07 mmol) and sodium ascorbate (6 mg, 0.03 mmol) followed by TMS-acetylene (231 μL, 1.67 mmol). The reaction mixture was heated to 70 °C for 1 h. The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL). The

10 combined organic extracts were washed with H₂O, brine, dried over MgSO₄, and condensed to give a yellow oil that was dissolved in THF (20 mL). TBAF 1M in THF (6.95 mL, 6.95 mmol) was added and stirred for 30 minutes. The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with H₂O, brine, dried over MgSO₄, and condensed to give a brown oil that was purified by flash chromatography using a

15 gradient of 10-60% EtOAc in hexanes to give intermediate 35 as a white solid (348 mg, 65 % yield). ¹H NMR (500 MHz, CDCl₃): δ 8.01 (q, *J* = 10 Hz, 2H), 4.31 (m, 1H), 3.95-3.82 (m, 4H), 2.83 (m, 3H), 2.27 (m, 1H), 2.03-1.95 (m, 2H), 1.90-1.75 (m, 3H), 1.71-1.63 (m, 1H), 1.67-1.39

(m, 10H), 1.35-1.26 (m, 1H), 1.13-1.07 (m, 1H), 0.97 (s, 3H), 0.78 (s, 3H). MS m/z 386.76 [M+H]⁺.

Steps 2 and 3: synthesis of intermediates 36 and 37

Intermediate **36** (MS m/z 341.86 [M+H]⁺) was prepared using the procedure used to prepare intermediates **20** and **30** above. Intermediate **37** (MS m/z 474.45 [M+H]⁺) was prepared using the procedure used to prepare intermediates **21** and **31** above.

Step 4: synthesis of compound 38


Compound **38** was prepared from intermediate **37** using the procedure used to prepare compound **1** above. ¹H NMR (500 MHz, DMSO-d₆): δ 9.74 (s, 1H), 8.53 (d, *J* = 6Hz, 1H), 8.17 (s, 2H), 8.03 (q, *J* = 10Hz, 2H), 7.90 (s, 1H), 7.69 (s, 1H), 6.38 (s, 1H), 4.52 (m, 1H), 2.33-2.11 (m, 3H), 2.12-1.85 (m, 5H), 1.72-1.40 (m, 8H), 1.30-1.20 (m, 2H), 1.15-1.08 (m, 1H), 0.97 (s, 3H), 0.92-0.87 (m, 1H), 0.51 (s, 3H). MS m/z 453.51 [M+H]⁺.


Step 5: synthesis of compound 39

Compound **39** was prepared from compound **38** using the procedure used to prepare compounds **8a**. ¹H NMR (500 MHz, DMSO-d₆): δ 9.76 (s, 1H), 8.57 (d, *J* = 6Hz, 1H), 8.21 (s, 2H), 8.06 (q, *J* = 10Hz, 2H), 7.92 (s, 1H), 7.72 (s, 1H), 4.58 (m, 1H), 3.02 (t, *J* = 10Hz, 1H), 2.33-2.11 (m, 3H), 2.06-1.82 (m, 5H), 1.69-1.37 (m, 10H), 1.33-1.22 (m, 2H), 1.13-1.04 (m, 1H), 0.95 (s, 3H), 0.92-0.87 (m, 1H), 0.53 (s, 3H). MS m/z 455.68 [M+H]⁺.

Example 8: (3*S*,8*R*,9*S*,10*S*,13*S*,14*S*,17*S*)-17-(isoquinolin-7-yl)-*N*,10,13-trimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-amine (46)

Scheme 7.





Step 1: synthesis of intermediate 40

To a solution of (3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-10,13-dimethylhexadecahydrospiro-

5 [cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolan]-3-amine (500 mg, 1.50 mmol) in THF (25 mL) was added Boc₂O (393 mg, 1.80 mmol) followed by DMAP (37 mg, 0.3 mmol). The mixture was stirred for 3 h. The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with H₂O, brine, dried over MgSO₄, and condensed to give a yellow oil that was purified by flash chromatography using a gradient of 5-20% EtOAc

10 in Hexanes to give intermediate 40 as a white solid (602 mg, 93% yield). ¹H NMR (500 MHz, CDCl₃): δ 6.42 (br, 1H), 3.92-3.81 (m, 4H), 2.06-1.89 (m, 1H), 1.80-1.52 (m, 10H), 1.46 (s, 9H), 1.41-1.18 (m, 10H), 1.08-0.90 (m, 2H), 0.81 (s, 3H), 0.79 (s, 3H). MS m/z 434.58 [M+H]⁺.

Step 2: synthesis of intermediate 41

To a solution of tert-butyl ((3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-10,13-

15 dimethylhexadecahydrospiro[cyclopenta[*a*]phenanthrene-17,2'-[1,3]dioxolan]-3-yl)carbamate (602 mg, 1.39 mmol) in DMF (10 mL) was added NaH 60% in mineral oil (83 mg, 2.08 mmol). The mixture was stirred for 30 minutes, then MeI (208 μL, 3.34 mmol) was added and stirred overnight. The reaction was quenched with H₂O and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with H₂O, brine, dried over MgSO₄, and condensed to

20 give a yellow oil that was purified by flash chromatography using a gradient of 5-30% EtOAc in Hexanes to give intermediate 41 as a white solid (602 mg, 93% yield). ¹H NMR (500 MHz,

CDCl₃): δ 3.95-3.82 (m, 4H), 2.75 (s, 3H), 2.02-1.93 (m, 1H), 1.84-1.50 (m, 10H), 1.48 (s, 9H), 1.45-1.18 (m, 10H), 1.10-0.90 (m, 2H), 0.86 (s, 3H), 0.82 (s, 3H). MS m/z 448.83 [M+H]⁺.

Steps 3 and 4: synthesis of intermediates 42 and 43

Intermediate **42** (MS m/z 404.31 [M+H]⁺) was prepared from intermediate **41** using the procedure used to prepare intermediates **20** and **30** above. Intermediate **43** (MS m/z 536.78 [M+H]⁺) was prepared from intermediate **42** using the procedure used to prepare intermediates **21** and **31** above.

Step 5: synthesis of intermediate 44

Intermediate **44** was prepared from intermediate **43** using the procedure used to prepare Compound **1** above. ¹H NMR (500 MHz, DMSO-d₆): δ 9.70 (s, 1H), 8.50 (d, *J* = 6 Hz, 1H), 8.25 (s, 1H), 8.19 (d, *J* = 6 Hz, 1H), 8.14 (d, *J* = 6 Hz, 1H), 8.04 (d, *J* = 8 Hz, 1H), 6.32 (s, 1H), 2.77 (s, 3H), 2.40-2.33 (m, 1H), 2.21-2.10 (m, 2H), 1.82-1.59 (m, 8H), 1.49 (s, 9H), 1.44-1.24 (m, 8H), 1.15 (s, 3H), 1.12-1.05 (m, 2H), 0.90 (s, 3H). MS m/z 515.63 [M+H]⁺.

Step 6: synthesis of compound 45


To a solution of tert-butyl ((3*S*,8*R*,9*S*,10*S*,13*S*,14*S*)-17-(isoquinolin-7-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)(methyl)carbamate (50 mg, 0.1 mmol) in DCM (10 mL) was added TFA (1 mL). The mixture was stirred for 30 min and the solvent removed in vacuo to give compound **45** as a beige solid that was used without further purification (40 mg, 98% yield). MS m/z 415.57 [M+H]⁺.

Step 7: synthesis of compound 46

Compound **46** was prepared from compound **45** using the procedure used to prepare compound **8a** above. 91% yield. MS m/z 417.37 [M+H]⁺.

Example 9: *N*-((3*S*,8*R*,10*S*,13*S*,14*S*,17*S*)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)-*N*-methylacetamide (47)

Scheme 8.




5 To a solution of (3*S*,8*R*,10*S*,13*S*,14*S*,17*S*)-17-(isoquinolin-7-yl)-*N*,10,13-trimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-amine **46** (20 mg, 0.048 mmol) in THF (3 mL) and sat. aq. NaHCO₃ solution (2mL) was added acetyl chloride (4μL, 0.058 mmol). The mixture was stirred for 30 minutes and then the reaction was quenched with H₂O and extracted with EtOAc (3 X 50 mL). The combined organic extracts were washed with H₂O, brine, dried

10 over MgSO₄ and condensed to give a yellow oil that was purified by reverse phase HPLC using a gradient of 1-80% MeCN in H₂O to give the title compound **47** as a brown solid (12 mg, 57% yield). ¹H NMR (500 MHz DMSO-*d*₆): δ 9.70 (s, 1H), 8.62 (d, *J* = 6Hz, 1H), 8.33 (d, *J* = 6Hz, 1H), 8.31 (s, 1H), 8.22 (d, *J* = 6Hz, 1H), 8.01 (d, *J* = 6Hz, 1H), 3.54 (m, 1H), 3.21 (s, 3H), 3.1 (t, *J* = 10Hz, 1H), 2.70 (s, 3H), 2.44-2.27 (m, 6H), 1.68-1.28 (m, 12H), 1.16-1.00 (m, 4H), 0.94 (s,

15 3H), 0.44 (s, 3H). MS *m/z*: 459.72 [M+H]⁺.

Example 10: Synthesis of 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-*N*-((3*S*,5*S*,10*S*,13*S*,14*S*,17*S*)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)-*N*-methyl-3,6,9,12-tetraoxapentadecan-15-amide (I-1)




5

To a solution of compound **46** (20 mg, 0.048 mmol) in DMF was added HATU (37 mg, 0.096 mmol) and 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oic acid (28 mg, 0.053 mmol) followed by DIEA (42 μ L, 0.24 mmol).

The reaction was stirred for 30 minutes and then injected directly onto the HPLC and purified using a gradient of 1-90% MeCN in H₂O to give the title compound **I-1** as a yellow solid (8 mg, 18% yield). ¹H NMR (500 MHz, DMSO): δ 11.09 (s, 1H), 9.71 (s, 1H), 8.60 (s, 1H), 8.36-8.29 (m, 3H), 8.19-8.16 (m, 1H), 7.99 (t, *J* = 5 Hz, 1H), 7.60-7.54 (m, 1H), 7.17-7.13 (dd, *J* = 5 Hz, 8 Hz, 1H), 7.04 (d, *J* = 6 Hz, 1H), 5.12- 5.03 (m, 1H), 4.27 (m, 1H), 3.64-3.59 (m, 4H), 3.54-3.45 (m, 14H), 2.99-2.84 (m, 2H), 2.79 (s, 3H), 2.06-1.95 (m, 3H), 1.83-0.91 (m, 24H), 0.77 (s, 3H), 0.43 (s, 3H). MS *m/z* 921.49 [M+H]⁺.

15

Example 11: Synthesis of 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)-N-((3*S*,10*S*,17*S*)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)-*N*-methylpropanamide (I-2)




5 Compound **I-2** was prepared from compound **46** and 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)propanoic acid as described above in

Example 10. ¹H NMR (500 MHz, DMSO): δ 11.10 (s, 1H), 9.67 (s, 1H), 8.59 (s, 1H), 8.31-8.24 (m, 3H), 8.15 (d, $J = 7$ Hz, 1H), 7.96 (t, $J = 5$ Hz, 1H), 7.76 (dd, $J = 5$ Hz, 8 Hz, 1H), 7.66-7.52 (m, 1H), 7.24-7.12 (m, 1H), 5.12 (m, 1H), 4.25 (m, 1H), 3.68 (m, 8H), 3.00-2.84 (m, 4H), 2.77 (s, 3H), 2.26 (m, 2H), 1.71-0.91 (m, 25H), 0.79 (s, 3H), 0.46 (s, 3H). MS m/z 832.79 [M+H]⁺.


10

Example 12: Synthesis of 3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)-N-((3*S*,10*S*,17*S*)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)-*N*-methylpropanamide (I-3)



15 Compound **I-3** was prepared from compound **46** and 3-(2-(2-((1,3-dioxo-2-(2-oxopiperidin-3-yl)isoindolin-4-yl)amino)ethoxy)ethoxy)propanoic acid as described above in **Example 10**.

Example 13: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-((7-(((3S,5S,10S,13S,14S,17S)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)(methyl)amino)heptyl)oxy)ethoxy)ethyl)amino)isoindoline-1,3-dione (I-4)




5

Compound I-4 was prepared by treating compound 46 and 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione with 1,6-dibromo hexane in the presence of a base, *e.g.*, potassium carbonate, DIEA, TEA, or the like, in a solvent, *e.g.*, polar aprotic solvent such as DMF.

10

Example 14. Synthesis of N-((3S,5S,10S,13S,14S,17S)-17-(isoquinolin-7-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-N-methyl-1-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-amide (I-5)

5



Compound **I-5** was prepared from compound **46** and 1-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oic acid as described above in **Example 10**. ¹H NMR (500 MHz, DMSO): δ 9.71 (s, 1H), 8.60 (s, 1H), 8.35-8.29 (m, 3H), 8.19-8.16 (m, 1H), 7.99 (t, $J = 5$ Hz, 1H), 7.61-7.57 (m, 1H), 7.16 (dd, $J = 5$ Hz, 8Hz, 1H), 7.04 (d, $J = 6$ Hz, 1H), 5.12- 5.03 (m, 1H), 4.27 (m, 1H), 3.64-3.45 (m, 18H), 3.01 (s, 3H), 2.99-2.91 (m, 2H), 2.80 (s, 3H), 2.06-1.95 (m, 3H), 1.83-0.91 (m, 24H), 1.16 (s, 3H), 1.06 (s, 3H), 0.76 (s, 3H). MS m/z : 935.71 [M+H]⁺.

Example 15: Biological activities of the compounds of the application

Compounds of the present application were tested in a competitive kinase binding assay by using commercially available assay system. For example, LanthaScreen[®] Eu Kinase Binding Assay (Invitrogen[™]) was used to measure the IC₅₀ of the compounds of the present application in displacing the Tracer from binding to the target kinase, by following the assay protocol from Invitrogen[™].

Biological activities of the Targeting Ligands of Table 1 are shown in Table 2 below. Biological activities of the bifunctional compounds are shown in Table 3 below.

Table 2.

Compound No.	Enzyme IC ₅₀ (nM)	Compound No.	Enzyme IC ₅₀ (nM)	Compound No.	Enzyme IC ₅₀ (nM)
1	B	2	E	3	G
4	F	5	E	6	G
7	G	8a	A	8b	C
9	G	10	B	11	D
12	G	13	G	14	F
22r	B	23	A	24	C
25	A	32	B	33	A
34	B	39	A	46	E
47	A				

IC₅₀ ratings: "A" ≤100 nM; "B" = 101-200 nM; "C" = 201-300 nM; "D" = 301-700 nM; "E" = 701-2,000 nM; "F" = 2,001-6,000 nM; "G" ≥ 6,001 nM.

5 Table 3.

Compound No.	Enzyme IC ₅₀ (nM)
I-1	B
I-2	B
I-3	C
I-5	D

IC₅₀ ratings: "A" ≤100 nM; "B" = 101-200 nM; "C" = 201-300 nM; "D" = 301-700 nM; "E" = 701-2,000 nM; "F" = 2,001-6,000 nM; "G" ≥ 6,001 nM.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the present application.

5

CLAIMS:

1. A compound or a stereoisomer or pharmaceutically acceptable salt of Formula X:




wherein:

the Targeting Ligand is capable of binding to cyclin-dependent kinase 8 (CDK8) and/or cyclin-dependent kinase 19 (CDK19);

the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and

the Degron is capable of binding to a ubiquitin ligase;

wherein the Targeting Ligand is of Formula TL-I:




wherein:

X is $-\text{O}-$, $-\text{NR}_5-$, or $-\text{Het}_2-$;


R_5 is H or C_1 - C_6 alkyl;

Het_2 is a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring comprising one or more additional heteroatoms selected from nitrogen, sulfur, and oxygen;

u, v, and w together form (i), (ii), or (iii):




y and z together form (iv) or (v):



Het_1 is heteroaryl comprising one or two 5- or 6-membered rings and 1-4 heteroatoms selected from nitrogen, sulfur, and oxygen, and optionally substituted with NH_2 ;

wherein the Targeting Ligand is bonded to the Linker via the $\text{---}\overset{\text{wavy}}{\text{C}}\text{---}$;

wherein the Degron is of Formula D1:



wherein:

Y is a bond, (CH₂)₁₋₆, (CH₂)₀₋₆-O, (CH₂)₀₋₆-C(O)NR₁₁, (CH₂)₀₋₆-NR₁₁C(O), (CH₂)₀₋₆-NH, or (CH₂)₀₋₆-NR₁₂;

Z₁ is C(O) or C(R₁₃)₂;

Z₂ is C(O) or C(R₁₃)₂;

R₁₁ is H or C₁-C₆ alkyl;

R₁₂ is C₁-C₆ alkyl or C(O)-C₁-C₆ alkyl;

each R₁₃ is independently H or C₁-C₃ alkyl;


each R₁₄ is independently C₁-C₃ alkyl;

R₁₅ is H, deuterium, C₁-C₃ alkyl, F, or Cl;


each R₁₆ is independently halogen, OH, C₁-C₆ alkyl, or C₁-C₆ alkoxy;

q is 0, 1, or 2; and

s is 0, 1, 2, or 3,


wherein the Degron is covalently bonded to the Linker via .

2. The compound of claim 1, wherein u, v, and w together form




(i)

3. The compound of claim 1, wherein u, v, and w together form




(ii)

4. The compound of claim 1, wherein u, v, and w together form




(iii)

5. The compound of claim 1, wherein y and z together form




(iv)




6. The compound of claim 1, wherein y and z together form (v).
7. The compound of claim 1, wherein X is $-O-$.
8. The compound of claim 1, wherein X is $-NR_5-$.
9. The compound of claim 8, wherein R_5 is methyl.
10. The compound of claim 1, wherein X is $-Het_2-$.
11. The compound of claim 1, wherein Het_2 is selected from aziridine, azetidine, pyrrolidine, dihydropyrrole, piperidine, piperazine, dihydropyridine, tetrahydropyridine, azepane, oxaziridine, oxazetidine, isoxazoline, isoxazolidine, oxazoline, oxazolidine, thiazoline, thiazolidine, isothiazoline, isothiazolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, morpholine, oxazinane, thiomorpholine, and thiazinane.
12. The compound of claim 1, wherein Het_2 is triazole.
13. The compound of claim 1, wherein Het_2 is morpholine.
14. The compound of claim 1, wherein Het_2 is piperazine.
15. The compound of claim 1, wherein Het_1 is selected from isoquinolinyl, quinolinyl, indazolyl, cinnolinyl, phthalazinyl, pyridinyl, pyridazinyl, indolyl, acridinyl, pyrazinyl, benzoquinolinyl, pyrazolyl, pyrrolyl, pyrimidinyl, purinyl, pyrrolopyrimidinyl, quinoxalinyl, and quinazolinyl.
16. The compound of claim 1, wherein Het_1 is 6-isoquinolinyl, 7-isoquinolinyl, 6-quinazolinyl, 6-phthalazinyl, 6-indazolyl, 6-indazolyl-3-amine, or 5-indazolyl.

17. The compound of claim 1, wherein Het₁ is 7-isoquinolinyl.

18. The compound of claim 1, wherein the Targeting Ligand is of Formula (iv(a)'), (v(a)'), (iv(a)'''), (v(a)'''), (iv(b)'), (v(b)'), (iv(b)'''), (v(b)'''), (iv(c)'), or (v(c)'), (iv(c)'''), or (v(c)'''):




19. The compound of claim 1, wherein the Targeting Ligand is of one of the following formulae:




wherein:

a, b, c, and d are each independently CR₆ or N; and
each R₆ is independently H or NH₂.

20. The compound of claim 1, wherein the Targeting Ligand is of one of the following formulae:




21. The compound of claim 1, wherein the targeting Ligand is of one of the following formulae:








wherein:





e and f are each independently CR₇ or N; and
each R₇ is independently H or NH₂.

22. The compound of claim 1, wherein the Targeting Ligand is any one of










23. The compound of claim 1, wherein the Linker is of Formula L0:



or a stereoisomer thereof, wherein

p1 is an integer selected from 0 to 12;

p2 is an integer selected from 0 to 12;

p3 is an integer selected from 0 to 6;



each W is independently a bond, CH₂, O, S, NH, or NR₁₉;

Z₃ is a bond, C(O), (CH₂)_jC(O)NH, CH₂, O, NH, or NR₁₉;

each R₁₉ is independently C₁-C₃ alkyl;

j is 1, 2, or 3; and

Q is a bond, CH₂, C(O), or NHC(O)CH₂,

wherein the Linker is covalently bonded to the Degron via the  next to Q, and covalently bonded to the Targeting Ligand via the  next to Z₃.

24. The compound of claim 23,

wherein:



p2 is 0;

p3 is 2;



each W is O;





Z₃ is C(O); and

Q is a bond;

wherein the Linker is covalently bonded to the Degron via the  next to Q, and covalently bonded to the Targeting Ligand via the  next to Z₃.

25. The compound of claim 1, wherein the Targeting Ligand (TL)-Linker is selected from:






p1 is an integer selected from 0 to 12;

p3 is 2; and

j is 1, 2 or 3.

26. The compound of claim 25, wherein the Targeting Ligand (TL)-Linker is



27. The compound of claim 1, wherein Z₁ is C(O).


28. The compound of claim 1, wherein Z₂ is C(O).

29. The compound of claim 1, wherein Z₁ and Z₂ are each C(O).


30. The compound of claim 1, wherein Z₁ is C(O) and Z₂ is CH₂.

31. The compound of claim 1, wherein Y is a bond.


32. The compound of claim 1, wherein the Degron is of the following formula:




(D1a),




(D1a'),




(D1b),




(D1b'),




(D1c),




(D1c'),




(D1d),




(D1d'),




(D1e),




(D1e'),




(D1f),




(D1f'),




(D1g),




(D1g'),




(D1h),




(D1h'),




(D1i),




(D1i'),




(D1j),




(D1j'),




(D1k),



(D1k'),




(D1l), or




(D1l').


33. The compound of claim 1, wherein the Degron is of the following formula:




(D1a),



(D1a'),




(D1g), or




(D1g')

34. The compound of any one of claims 1-33, wherein R₁₃ is H.


35. The compound of claim 1, having the following structure:




36. The compound of claim 1, having the following structure:



37. The compound of claim 1, having the following structure:



38. The compound of claim 1, having the following structure:



39. A pharmaceutical composition comprising the compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
40. The compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, for use in inhibiting or modulating cyclin-dependent kinase 8 (CDK8) and/or cyclin-dependent kinase-19 (CDK19).
41. The compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, for use in treating or preventing a disease in which one or more of CDK8 and CDK19 is overexpressed.
42. The compound for use of claim 41, wherein the disease is cancer or a proliferation disease.
43. The compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for modulating one or more of CDK8 and CDK19 or treating or preventing a disease in which one or more of CDK8 and CDK19 is overexpressed.
44. A kit comprising a compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, and instructions for use in treating cancer.
45. Use of a compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, for inhibition or modulation of cyclin-dependent kinase 8 (CDK8) and/or cyclin-dependent kinase-19 (CDK19).
46. Use of a bifunctional compound of any one of claims 34-38, or a stereoisomer or pharmaceutically acceptable salt thereof, for treatment or prevention of a disease in which one or more of CDK8 and CDK19 is overexpressed.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5






FIG. 6



I-2


FIG. 7



I-5

FIG. 8

Jurkat



pS727-STAT1

CDK8

Actin

0.1 μM

1 μM

0.1 μM

1 μM

—

—

6 h

24 h